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ABSTRACT 
 Glioblastoma multiforme (GBM) is the most common and lethal primary brain 
cancer, killing approximately 17,000 patients in the US each year. Despite innovations in 
drugs and targeted therapies, the mortality rate has remained unchanged for over two 
decades, largely due to the impermeability of the blood brain barrier (BBB) and the poor 
response of GBM to most chemotherapeutics. Small interfering RNA (siRNA) has 
demonstrated clinical success in modulating the expression of oncogenic genes and is 
emerging as an attractive therapeutic against GBM. However, siRNA suffers from in vivo 
delivery issues such as sensitivity to enzymatic degradation, rapid clearance, and exclusion 
by the BBB. These challenges can be addressed by using nanoparticles which are gaining 
prominence in cancer therapy for their capacity to package a broad spectrum of drugs, 
extend circulation times, and modify the surface with a variety of targeting moieties. 
This thesis introduces a lipid-coated calcium phosphate nanoparticle (LCaP) designed for 
intracellular delivery of siRNA as well as transcellular transport across the BBB. The 
calcium phosphate core entraps the siRNA and protects it from nucleases, while the lipid 
coating shields charges to provide colloidal stability and an area for ligand attachment to 
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facilitate receptor-mediated transcytosis.  
 LCaPs were fabricated and characterized for their physiochemical properties; by 
altering the calcium to phosphate ratio, LCaP features such as size, surface charge, and 
siRNA loading could be tailored. LCaPs were then used to deliver siRNA in vitro and 
demonstrated successful and sustained knockdown of a reporter gene stably transfected in 
a cancer cell line. In addition, siRNA against the epidermal growth factor receptor variant 
III (EGFRvIII), a mutation specific to GBM, was delivered via LCaPs and demonstrated 
dose-dependent protein knockdown and a subsequent reduction in cell viability, indicating 
the potential of EGFRvIII as a therapeutic target. In order to improve BBB penetration, 
LCaPs were decorated with the targeting peptide, Angiopep-2, which binds to the low 
density lipid receptor related protein 1 that facilitates molecular transport across the BBB. 
BBB penetration was evaluated as a function of Angiopep-2 density in a BBB model 
incorporating human-derived induced pluripotent cells differentiated into brain endothelial 
cells along with immortalized human cancer cells. The BBB platform enabled more 
physiologically relevant evaluation of LCaP penetration and could be used as a screening 
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This dissertation was motivated by the drastically poor clinical outcomes of brain 
cancer and was primarily driven by two major questions: Is there is a more effective 
treatment option for brain cancer and is there a more effective way to deliver (and assess 
delivery of) that treatment into the brain? In the search for an answer, siRNA therapy arose 
as a promising technology. With success in treating other types of cancers and disease, 
RNA use is gaining momentum but still faces delivery challenges in vivo. This thesis 
introduces a lipid-coated calcium phosphate nanoparticle that hybridizes RNA transfection 
technologies and combines benefits utilized in cancer nanomedicine to address some of 
those challenges. The particle further incorporates the targeting peptide Angiopep-2 to take 
advantage of natural brain transport mechanisms across the blood-brain barrier (BBB). To 
assess penetration and the therapeutic efficacy of the nanoparticle, a fully human-derived 
in vitro Transwell blood brain barrier model was established. These two platforms have the 
potential to expand treatment options for brain disease and improve the prediction and 
translation of treatment success in patients. 
 
1.2 Brain Cancer Background 
1.2.1 Brain Cancer Statistics 
Brain cancer is the second leading cause of cancer-related deaths in children ages 
0 to 14, affecting 21% of those patients in the US each year [1, 2]. In adults, brain and 
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central nervous system cancers only account for 1.4% of all cancer cases [3], but have a 
disproportionality high mortality rate. Glioblastoma multiforme (GBM) makes up 80% of 
malignant brain cancers and is the most aggressive form, with a median survival time of 
14 months from the time of diagnosis and a 5-year survival rate of less than 3%. This rate 
has remained relatively stagnant in the past two decades, despite advances in new 
treatments [4]. One of the main reasons for this is the challenge of accessing the brain.  
 
1.2.2 Current Treatments for Glioblastoma 
The current standard of care is surgical resection followed by adjuvant radiation 
and/or chemotherapy [5, 6], but all treatment options have severe limitations. Gliomas are 
highly invasive with poorly defined tumor margins, which makes complete resection of the 
tumor rarely possible without damage to delicate and necessary brain structures [1, 7]. 
When surgery is possible, the balance between removing diseased tissue and preserving 
brain function results in residual tumor cells that almost inevitably lead to cancer 
recurrence. To combat this, rounds of radiation and chemotherapy are administered post-
operation. However, radiation dose must be restricted to avoid impairment of cognitive 
function and formation of secondary malignancies [8]. Moreover, less than 1% of most 
systemically administered chemotherapies penetrates the blood brain barrier [9], making 
treatment much less effective with brain malignancies compared to other cancer types. 
Additionally, chemotherapy can have debilitating systemic side effects due to off-target 
effects on healthy tissue. Thus there is a strong need to develop treatments that can 
penetrate the BBB to specifically and effectively kill cancerous cells while minimizing 
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harm to healthy tissue. 
As part of the battle against GBM, new therapeutic strategies are being developed. 
The general trend towards personalized medicine in cancer has led to gene sequencing and 
genetic stratification, and a turn towards targeted medicines. Unlike traditional 
chemotherapy drugs, which aim to non-specifically kill rapidly dividing cells (a hallmark 
of mutated cancer cells but which leads to off-target attacks on healthy, naturally rapidly 
dividing cells), targeted therapies focus on other hallmark pathways hijacked in cancer, 
such as angiogenesis, evasion of apoptosis, and invasion or metastasis [10, 11]. The ability 
to selectively target malignant cells and thus spare healthy cells and tissues has prompted 
the advancement of several therapeutics, such as monoclonal antibody targeting, small 
molecule inhibitors, aptamers, gene/RNA therapy, immunotherapy, and cancer vaccines 
[12]. RNA therapy, in particular, is attractive for its ability to target proteins that were once 
considered “undruggable” [13, 14]. New methods of packaging and advances in genomics 
have seen a revival in RNA/gene therapies, which despite clinical setbacks in the early 
2010’s, led to the first FDA approved siRNA therapy in 2018 [15]. Thus RNAi 
demonstrates exciting potential as a new treatment class for GBM. 
 
1.3 RNA Interference and Delivery Challenges 
Since its discovery in 1998 By Craig and Mello [16], RNA silencing has become a 
powerful tool in the field of gene therapy. As an endogenous process in animal cells, RNA 
silencing post-transcriptionally regulates expression of protein by degrading messenger 
RNA and inhibiting translation. Precursor RNA (short single stranded hairpin loops or 
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double stranded RNA) is cleaved by either Drosha and/or DICER into 21-23 bp double 
stranded segments known as either microRNA (miRNA) or small interfering RNA 
(siRNA), depending on the precursor molecule. The miRNA/siRNA binds to a group of 
proteins to form the RNA induced silencing complex (RISC), which uses one of the 
miRNA/siRNA strands as a guide to bind and cleave complementary mRNA. In animals 
(vs plants), miRNA actually uses a different mechanism than siRNA for gene regulation 
and binds with only partial complementarity to the 3’ untranslated region (UTR) of 
mRNAs, physically preventing translation and activating degradation [17]. Because of this 
reduced specificity and greater chance for unintended off-targets, miRNA has seen less use 
in clinical trials compared to siRNA. The promise of siRNA therapy and its power to 
specifically and potently impair the expression of virtually any gene in the human genome 
makes RNAi an attractive option for treating various diseases, including cancer. Proteins 
once considered “undruggable” by conventional small molecules, are now accessible, 




Figure 1. A schematic of the siRNA and miRNA silencing mechanisms.  [18] 
 
However, exploitation of RNAi in vivo to date has primarily been hindered by 
delivery constraints [19, 20]. Oligonucleotides (miRNA, siRNA, shRNA, plasmids, etc.) 
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are subject to rapid degradation by nucleases in the blood, the negatively charged 
phosphate backbone induces rapid clearance by the immune system, and the relatively large 
size (~14kDa for siRNA) plus charge repulsion between the backbone and cell lipid 
membrane restricts cellular internalization [19-23]. Efforts are ongoing to chemically 
modify RNA to improve stability or to directly conjugate RNA to targeting peptides or 
antibodies for uptake [24], but these methods still face the problem of exposed charge and 
clearance in vivo. Biocompatible nanoparticles can be loaded with siRNA and thus may be 
used as an alternative to chemical modification for siRNA delivery. The nanoparticles can 
be engineered to avoid rapid clearance and to take advantage of receptor-mediated 
transport through the BBB, thus improving delivery of the therapeutic to brain tumors.  
 
1.3.1 Nanoparticles for siRNA Delivery 
The ideal nanoparticle should carry and protect the RNA, extend circulation time 
to reach the tumor site, facilitate internalization, and deliver the payload into the cytosol of 
the intended cells with minimal harm to healthy tissue. The physiochemical properties of 
NPs can be tailored by its composition, size, shape, and surface charge, which will affect 
the pharmacokinetics and biocompatibility within the body as briefly summarized in 
Figure 2. While there is a plethora of nanoparticle types varying in composition (not to 
mention size, shape, function, and complexity), each has their own benefits and 
disadvantages. The three most commonly used vehicles for oligonucleotide delivery are 
particles composed of polymers, lipids, or calcium phosphate. These formulations suffer 




Figure 2. A schematic of the physiochemical properties of nanoparticles  that governs the 
pharmacokinetics in the body. RES = reticuloendothelial system. [25] adapted from [26].  
 
containing media and toxic effects. Recognizing these shortcomings, this dissertation 
formulates a core-shell nanoparticle composed of calcium phosphate (core) and 
phospholipids (shell) that resolves the limitations for each respective component. 
 
Polymer-based Carriers 
Polymers frequently have been used for oligonucleotide transfection, and include 
both natural (chitosan, collagen, gelatin, dextran) and synthetic (polyethyleneimide (PEI), 
polyamidoamine, polybrene, poly-L-lysine) materials [27, 28]. In general, most polymers 
used for transfection are cationic and added in excess to bind electrostatically to RNA (or 
DNA), creating a polymer/RNA complex, or polyplex [29]. The net positive charge enables 
attraction and physical interaction with the cellular membrane, promoting internalization 
of the RNA[30]. The high molecular weight and charge density allow for condensation and 
higher packing of RNA, but also results in cellular toxicity due to destabilization of the 
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membrane, generation of harmful reactive oxygen species, and stimulation of caspase 
activity that leads to apoptosis [31, 32]. Historically, polyplexes have proven unsuitable 
for in vivo transfection due to destabilization in serum, non-specific interactions and rapid 
clearance from circulation [30, 33]. Although there is continuing research to improve NP 
polyplex serum stability as well as delivery in vivo, researchers have investigated the use 
of lipid-based nanoparticles as a viable alternative. 
 
Lipid-based Carriers 
Lipid-based NPs include lipoplexes and liposomes. Lipoplexes, similar to 
polyplexes, are cationic lipids complexed to RNA molecules. Several commercial 
transfection reagents (Lipofectamine, Dharmafect, Oligofectamine) are formed from 
cationic lipids. These lipids (e.g. DOTAP, DOTMA, PMMA) consist of a positively 
charged hydrophilic head group, a linker, and hydrophobic tails. They spontaneously 
interact with RNA and self-assemble to form alternating bilayers or hexagonal 
“honeycomb” lattices (Figure 3a) [29]. Liposomes, on the other hand, are phospholipid 
bilayers with an aqueous core in which the RNA can reside (Figure 3b). Liposomes are 
attractive for their biocompatibility/low immunogenicity, customizable shell components 
(i.e. neutral or fusogenic lipids), and capacity to add targeting ligands easily to the 
surface[34, 35]. However, liposomes and lipoplexes suffer from inefficient loading of 
oligonucleotides, which has hindered translation of the technology. A major goal of this 
thesis is to address this limitation by combining an efficient process for condensing siRNA 




Figure 3. Diagram of lipid-based siRNA carriers. a) the lipoplex bilayer and honeycomb 
structures [29] and b) a liposome. [36] 
 
Calcium Phosphate Precipitates 
First introduced in 1973 [37], calcium phosphate is a routinely used transfection 
agent favored for its ease of synthesis, dissolution at acidic pH, and tolerance in the body 
[38-41]. Calcium phosphate complexes electrostatically with DNA or RNA and enhances 
delivery by adhering to the cell surface where it is internalized by ion channel mediated 
endocytosis [42]. However, like other cationic agents, calcium phosphate suffers from 
colloidal instability, in vivo toxicity and non-specific interactions [43, 44]. Several 
approaches have been made to improve calcium phosphate delivery, including size 
reduction, addition of stabilizing molecules (polymers, saccharides), or coating with a 
protein- or lipid-based shell [38, 45-47]. A lipid coating is particularly attractive since it 
can shield charges to stabilize the particle structure and size, improve biocompatibility in 
the body, and generate a modifiable surface for functionalization. Previous work by the 
Huang group demonstrate a microemulsion precipitation method for fabrication of various 




this method, this dissertation develops a targeted nanoparticle for BBB penetration and 
delivery of siRNA to GMB. The hybrid nanoparticle is characterized for its physiochemical 
properties and evaluated for the feasibility of this delivery strategy through a series of in 
vitro experiments. 
 
1.3.2 siRNA in Disease Treatment and Cancer Therapy  
The first FDA approved siRNA therapy was passed in 2018, and the second last 
month in November 2019 [15, 50, 51]. While neither of these were for cancer indications, 
they are paving the way for future RNA medicines. The siRNA landscape has been 
predominantly focused on treating diseases for the eye (direct injection) and liver (easier 
accumulation), with ~30% of research focused on cancer treatment [18, 52-55]. Specific 
genes are upregulated in cancer, causing overexpression of proteins and stimulation of 
downstream pathways. By reducing the expression to normal levels, siRNA can help 
reverse or mitigate these effects through silencing of the overexpressed genes/proteins. 
Other benefits of siRNA are that it is relatively easy to produce (compared to antibodies 
and small biologics), genetic targets are easier to sequence or define, there is no need for a 
cellular or protein binding target, and all cells generate the required siRNA machinery. 
Current siRNA cancer therapies under clinical investigation include oncogenetic targets 
for the liver (VEGF, KSP, myc) and pancreas (PKN3, KRAS) with additional studies in 




1.3.3 EGFRvIII as a GMB Target 
A common mutation in epithelial cancer cells is the overexpression of epidermal 
growth factor receptor (EGFR) that leads to increased proliferation, growth, and signaling 
of other tumorgenic pathways. EGFR is a protein in the tyrosine kinase receptor family 
that consists of an extracellular domain for ligand binding, a transcellular domain through 
the cell membrane, and an intracellular domain for internal signaling. In gliomas, EGFR 
mutations account for up to 63% of all genetic alternations [60]. Of that subset, the 
EGFRvIII variant is the most common occurring 60-70% of the time [61]. In the brain, this 
variant is expressed only by malignant cells [60], making it an ideal molecular target for 
treating GBM. The EGFRvIII variant results in the truncation of the extracellular portion 
(due to in-frame deletion of exons 2–7), causing constitutively active signaling [62, 63]. 
Besides inducing growth and proliferation, EGFRvIII effects numerous key downstream 
signaling pathways resulting in reduced apoptosis, increased invasiveness, and increased 
angiogenesis [60, 62]. Furthermore, EGFRvIII has been implicated in contributing to the 
heterogeneity of gliomas by acting on neighboring cells that express the normal EGFR wild 
type phenotype, and causing activation of pro-tumor cascades in healthy cells [64].  
Current research with antibodies and small molecule inhibitors against EGFR and 
EGFRvIII demonstrate promising results against cell lines, but few have yet to significantly 
impact GBM survival or response in clinical trials on their own [60, 61, 65]. Other EGFR-
targeted approaches, such as peptide-based vaccines and RNA silencing, generating more 
encouraging results. Vaccines have entered Phase III clinical trials [63], and while RNA 
based therapies against GBM have not yet reached human patients, intracranial xenograft 
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tumors models in mice displayed up to 90% gene silencing, 19-29% tumor reduction, and 
90% increased survival [66]. Thus the positive in vivo results along with the role of 
EGFRvIII in tumorgenesis and its specificity to GBM make it an ideal candidate for siRNA 
therapy. 
 
1.4 The Blood Brain Barrier (BBB) 
1.4.1 Role of the BBB 
The major obstacle in treating diseases of the brain is the BBB, which exists to 
maintain the chemical and electrical homeostasis for neural signaling, as well as protect 
the brain from toxins and pathogens [67, 68]. As shown in Figure 4, the BBB is a physical 
biological barrier primarily composed of endothelial cells that line the cerebral capillaries. 
These brain endothelial cells are characterized by high expression of tight junction proteins 
and the lack of fenestrations, both of which contribute to the selective permeability of 
compounds from circulation to the brain [45, 46]. Pericytes and astrocyte endfeet also 
contribute to the tightness and polarization of the barrier [69-71]. In fact, the BBB so 
closely controls the exchange of ions, necessary nutrients, and wastes that less than 98% 
of small molecules and 100% of large molecules are prevented from passing through 
unaided [72]. This poses an enormous problem for most cancer therapeutics, including 




Figure 4. Diagram of the structure of the BBB.  [73] 
 
1.4.2 Current Strategies to Circumvent the BBB 
While several invasive approaches (surgical implantation, intracranial injection, 
convection enhanced delivery [74-77]) have been used to deliver therapeutics into the 
brain, they require a craniotomy to open the skull for access to the organ. Less invasive 
procedures will simplify treatment administration and improve patient recovery and quality 
of life. Current non-invasive strategies include temporarily permeabilizing the BBB using 
disruptive agents (i.e. mannitol) or ultrasound-driven microbubbles (i.e. cavitation), 
chemical modification to improve lipophilicity and cellular diffusion, and targeting using 
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antibodies or proteins [78-80]. Unfortunately, these strategies each have their own 
drawbacks. Ultrasound-mediated disruption of the BBB is guided with MR imaging and 
thus requires MR-compatible transducers that are available only in a few specialized 
treatment centers. Improving lipidization increases non-specific uptake by cells before the 
molecules reach the BBB endothelium. Antibodies and proteins are limited by the 
discovery and availability of targetable binding sites (i.e. membrane-bound receptors), but 
are currently the most promising approach. In particular, peptide-based strategies that take 
advantage of the brain’s natural transport system are gaining momentum as more is learned 
about the brain. 
 
 




The brain uses 4 main mechanisms to shuttle in necessary nutrients and remove 
waste solutes: 1) passive diffusion of small (<400 Da), lipophilic solutes, 2) carrier-
mediated transport (CMT) of ionic metabolites (e.g. glucose, amino acids, nucleosides, 
vitamins), 3) adsorptive(-mediated) transcytosis (AMT) (e.g. serum proteins), and 4) 
receptor-mediated transcytosis (RMT) of macromolecules (e.g. growth factors, hormones, 
lipoproteins) [21, 45, 60, 81]. In more detail, CMT is an active process that uses membrane 
embedded proteins to shuttle molecules across the lipid bilayer. The proteins are located 
on both the luminal capillary side of the endothelial cell membrane and the abluminal brain 
side, allowing for transport of solutes in and out of the brain. CMT is ideal for smaller 
molecules that will fit within the protein channel and is usually driven by ion gradients or 
ATP [61]. AMT is an active, but non-specific process in which positively charged 
molecules adsorb and are internalized by vesicles through contact with the negatively 
charged cell surface. Cationic transfection agents and cell penetrating peptides are thought 
to use AMT to enter cells, but this transport method can cause cellular toxicity [82]. RMT 
is also an active transport process, but is carried out by specific receptors bound to the cell 
surface. Binding of the appropriate ligand molecule activates endocytosis and vesicle 
trafficking through the cell to the opposite end. There the endosome fuses to the membrane 
and releases the ligand into the brain tissue. Because an endosome can engulf larger 
molecules, RMT is an ideal pathway for nanoparticle transport through the BBB. 
Conjugation of the ligand to the desired cargo (i.e. drug, nanocarrier, etc.) will enable both 
molecules to be transported via RMT [9, 62, 83-85].  
One such RMT pathway is mediated by the low density lipid receptor related 
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protein 1 (LRP1) which normally facilitates transport of lipids, clearance of amyloid 
proteins, and is involved in signal transduction and regulating protein kinases. [86-89]. 
Reportedly LRP1 is upregulated on brain endothelial cells as well as in glioma cells, which 
could enable both BBB penetration and internalization by malignant cells [2, 90] [86, 88, 
89]. A family of peptides labeled Angiopeps were derived from the Kuntiz domain of 
aproptinin, a natural ligand of LRP1 [90, 91]. Angiopep-2, in particular, was found to 
increase internalization through the BBB (7-fold increase compared to aprotinin in situ) 
[91] and has been used to facilitate transport of a variety of cargo in recent years [92-100]. 
Therefore, incorporation of Angiopep-2 into the hybrid siRNA nanoparticle can be 
analyzed for the advantages of its RMT properties. 
 
1.4.3 Blood Brain Barrier Models 
Ethical human testing (via clinical trials) is one of the last stages in the development 
of anti-cancer therapeutics and is tightly regulated, costly, and time-consuming.  Therefore, 
it is beneficial to predict the response of potential treatments prior to human testing by 
mimicking human anatomy and/or physiology using modeling approaches. These include 
in vitro cell approaches, animal studies, as well as in silico computational predictions. All 
have their benefits and disadvantages. While computational approaches are useful, 
empirical data are usually required to test the accuracy of the algorithms. Animal studies 
(mouse, rat, rabbit, pig, monkey, etc.) are more physiologically representative of the 
complex interactions between organ systems, but can be expensive and may not translate 
well to the equivalent disease progression in humans. In vitro models are more cost- and 
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resource-effective than animal models, and can still be relevant with the right parameters. 
Overall, models that most closely mimic human (disease) features should improve 
treatment success at the clinical research level. Until recently, in vitro models of the human 
BBB have been scarce, and animal-based models were leaky compared to the in vivo BBB. 
A goal of this thesis was to address this limitation by establishing and characterizing an in 
vitro BBB model composed of primary human brain endothelial cells, which could be 
utilized for evaluating ANG-mediated transport of siRNA-loaded LCaP across the barrier. 
 
In vitro BBB Model System(s): The Transwell 
Because animal models are expensive, more complicated to handle, and less easily 
scalable, this dissertation uses an in vitro model, specifically the Transwell model. Various 
types of in vitro BBB systems exist, from 2D static culture to microfluidic systems with 
flow to 3D self-assembling architecture [101, 102], but the Transwell system is one of the 
most common and straightforward to use. First developed by Boyden in 1961 to study 
leucocyte chemotactic migration [103, 104], the Transwell (or Bodyen assay) consists of a 
well and a well insert with a semi-permeable membrane support that allows the flow of 
fluid and solutes from one compartment to the other. Cells can be grown on one or both 
sides of the membrane (which come in different materials and pore sizes) to mimic the 
BBB and cells can be seeded onto the bottom well to represent a brain target (ie: a tumor). 
Monoculture, co-culture (contact or non-contact), tri-, and even quad-culture systems exist 





Figure 6. The Transwell BBB system showing various cell culturing methods. [105] 
 
There are various benchmarks for a BBB model such as barrier function 
(permeability, efflux transport), structure (geometry, flow), cell function (expression of 
tight junction markers and receptors), and microenvironment (extracellular matrix, co-
culture) [106]. For NP delivery, the largest hurdle is the barrier impermeability, and so the 
main focus for this dissertation will be on barrier tightness. Two methods to characterize 
the BBB tightness include transendothelial electrical resistance (TEER) and solute 
permeability (described more in Chapter 5). Briefly, TEER measures the resistance across 
the cell layer, with a higher TEER value representing a more intact and tight BBB. 
Permeability coefficient studies are conducted by measuring the flux of a small solute 
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through the BBB over time. As mentioned before, the cell type can have a large influence 
on barrier properties, including TEER and permeability.  
 
Cell Types for (Transwell) BBB Models 
Since the first isolation of brain microvascular endothelial cells (BMECs) from rat 
brain capillaries in the 1980s, one of the major impediments with advancing in vitro BBB 
models has been finding a cell source that is readily accessible, easy to culture, and can 
accurately recapitulate human BBB features and tightness [81, 101, 106, 107]. Options 
include primary brain cells, immortalized cell lines, and more recently human stem cells. 
Primary brain ECs are generally harvested from animal sources (rat, cow, pig), as human 
brain tissue is difficult to procure. They generate some of the highest TEER values (500-
1500 Ω∙cm2, depending on culture conditions), but are difficult to extract, prone to 
contamination by other cell types, experience batch to batch variability, and can lose their 
properties when propagated in vitro [105, 108]. Immortalized cell lines derived from both 
animals and humans (e.g. bEND.3, cEND, hCMEC/D3) are easier to maintain, but generate 
much lower TEER (10-300 Ω∙cm2) and may not express particular BMEC biomarkers 
[109, 110]. For both primary and immortalized BMECs, BBB tightness can be improved 
by the addition of astrocytes, astrocyte-conditioned media, and/or pericytes, but still do not 
reach the physiological level estimated of the human BBB  (>2000 Ω∙cm2) [111]. More 
recently, human stem cells from umbilical cord blood or pluripotent cells have been used 
to generate BMECs [102, 112]. The protocols published by the Shusta group (2012, 2015) 
used BMECs differentiated from induced pluripotent stem cells (iPSC) to establish 
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monoculture BBB models with TEER measuring 1000-3000 Ω∙cm2 [112-114]. These 
results have generated considerable excitement in the BBB field, and serve as a blueprint 




As mentioned earlier, GMB is a highly lethal brain disease with limited non-
invasive, effective treatment options. There is a critical need to develop new therapies that 
can efficiently bypass the BBB and treat the tumor. New therapeutics like siRNA appear 
to have the capability to revolutionize human health, but suffer from in vivo delivery issues. 
Polymer and calcium phosphate delivery agents have the ability to carry greater amounts 
of siRNA while conventional lipid NP systems can provide exceptional biocompatibility, 
a modifiable surface for peptide targeting, and flexibility for in vivo use but suffer from 
poor loading efficiency. By using the benefits of both to rationally engineer a lipid-coated 
calcium phosphate nanoparticle decorated with Angiopep-2, the body’s natural systems for 
altering gene expression (siRNA) and entering the brain (RMT) can be harnessed as a 
potential treatment strategy against GBM. The creation of this proposed nanoparticle 
platform holds potential to greatly impact the field of gene delivery and brain disease. 
In addition, in vitro BBB models have been unable to fully recapitulate the human 
BBB, particularly the restrictiveness of the in vivo barrier. Recent stem cell techniques have 
made it possible to develop a BBB model using human-derived brain endothelial cells that 
can reach physiological levels of tightness. By using a fully human cell model, the 
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permeability of the LCaP and its potential therapeutic efficacy in vivo can be better 
assessed. In addition to being more cost and resource effective than animal models, the 
utilization of this model should enable more realistic screening and more successful 




PROJECT OVERVIEW AND SPECIFIC AIMS 
2.1 Motivation and Scope/Overview  
This dissertation was motivated by the difficulty in treating glioblastoma 
multiforme cancer, and seeks to combine and apply recent advances in nanomedicine to 
address the problem. In scope, this project sought to answer two questions: 1) How can 
nanoparticles (NPs) be used to deliver siRNA effectively and efficiently into cells for 
oncogene silencing? and 2) How can NPs more effectively cross the blood brain barrier 
(BBB)? The first half of the thesis introduces the lipid-coated calcium phosphate 
nanoparticle, while the second half explores the use of the RMT ligand, Angiopep-2 in an 
in vitro BBB model composed of primary human brain endothelial cells. The fundamental 
experiments guiding this work are detailed in the specific aims below. 
 
2.2 Specific Aims 
Aim 1: Fabricate and characterize a lipid-coated calcium phosphate nanoparticle 
(LCaP) for siRNA delivery. 
The first aim focuses on the development of the lipid-coated calcium phosphate 
nanoparticle. Parameters of the fabrication process are explored and the effect of the 
calcium to phosphate ratio on NP size and siRNA loading is tested. Additionally, LCaP-
mediated siRNA delivery and gene silencing is validated against the reporter green 




Aim 2: Evaluate particle delivery in vitro and determine the therapeutic effect of 
siRNA-induced EGFRvIII silencing 
This aim evaluates the therapeutic potential of the GBM-specific protein, EGFRvIII. Cell 
lines expressing EGFRvIII are first verified for expression and silenced using a commercial 
transfection agent. LCaPs are then used to deliver anti-EGFRvIII siRNA to cells, and 
analysis of the subsequent protein expression and cell viability is analyzed in a dose- 
dependent manner.  
 
Aim 3: Establish an in vitro model of the human BBB and evaluate receptor-mediated 
transcytosis of surface-modified LCaP and siRNA-induced silencing  
Aim 3 explores the effect of ANG surface density on transcytosis in a Transwell BBB 
model. Human-derived induced pluripotent stem cells (iPSCs) are differentiated into brain 
endothelial cells (BMECs) for use in a Transwell BBB model, which is characterized by 
TEER and dextran permeability measurements. Angiopep-2 is used to decorate LCaPs to 
measure their permeability and accumulation across the BBB model in comparison to NPs 
without the ligand. Lastly, GFP-expressing cancer cells are cultured beneath the BBB 
model to investigate ANG-LCaP-mediated RNA delivery and silencing after penetrating 





FABRICATING A LIPID-COATED CALCIUM PHOSPHATE NANOPARTICLE 
The goal of the first aim was to fabricate and optimize a lipid coated calcium 
phosphate nanoparticle platform for delivery of siRNA. Experiments to measure the effect 
of the calcium phosphate ratio on LCaP characteristics such as size, charge, and loading 
were be performed. Additionally, in vitro tests were conducted to assess cell internalization 
of the LCaPs by MDA MB 231 cancer cells, as well as delivery of the siRNA and 
subsequent gene silencing.   
 
3.1 LCaP Background 
Calcium phosphate has long been used as an in vitro transfection agent to deliver 
DNA and RNA into cells[115]. The precipitates are easy to synthesize, requiring only the 
mixture of a calcium solution with a phosphate solution. DNA or RNA added to the mixture 
are condensed and efficiently loaded into the CaP complexes. However, one of the major 
drawbacks with CaP precipitation is its rapid aggregation in aqueous media [43]. 
Therefore, coating the CaP complex with a lipid shell to prevent aggregation will improve 
stability of the NP. The lipid shell also provides a surface for conjugating targeting moieties 
and shields the cationic charges for improved biocompatibility in vivo. Moreover, lipids 
with desired physicochemical properties and/or function can be selected for the shell, thus 
imparting functionality such as stealth (PEGylation) or responsiveness to certain triggers 
(pH- or temperature-sensitivity) to the NP. Additionally, CaP itself is biodegradable, and 
is naturally found in the human body in bones and teeth [116]. CaP is soluble in acidic 
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environments, and should dissolve to release siRNA once internalized in the endosome or 
lysosome, which have a pH range of 4.5-6.5. It is hypothesized that dissolution of CaP (and 
other common transfection cationic agents in the endosome) promotes the “proton-sponge 
effect”, a process in which the release of ions generates an osmotic imbalance and influx 
of water, causing the endosome to burst and release its contents (i.e. siRNA) into the 
cytoplasm. 
The particle and fabrication scheme utilized in this dissertation was based on a 
process reported by the Huang group [48, 49], with slight modifications. In brief, calcium 
and phosphate are each separately complexed with siRNA, then dispersed in an oil phase 
to form oil-in-water droplets. The two oil phases are mixed together, allowing the Ca and 
P droplets to merge and precipitate to form a nano-sized, siRNA-containing calcium 
phosphate core. Lipid, which was added to the phosphate emulsion (prior to precipitation), 
forms a monolayer shell around the core due to electrostatic interactions and hydrophobic 
self-assembly. The micelle-like core is collected and washed to remove unincorporated 
reagents, and a second lipid layer is added to form a bilayer that is stable in aqueous and 
serum-containing media and can be modified for targeting or other functions. A schematic 




Figure 7. Schematic of the LCaP fabrication process. 
 
3.2 Materials and Methods 
3.2.1 Fabricating the Lipid-Coated Calcium Phosphate Nanoparticle 
Preparations and Stock Solutions for LCaP Synthesis 
In general, stock solutions for nanoparticle fabrication were made prior to starting 
synthesis and replenished as needed. When possible, all material and work was performed 
in a nuclease-free environment with nuclease-free materials. RNAseZAP, DNAseAway 
and RNAseAway [ThermoFisher Scientific, AM9782, 7002PK] were used according to 
manufacturing instructions to clean glassware, pipets, and bench surfaces. De-ionized 
water (diH2O) treated with diethyl pyrocarbonate (DEPC) [Sigma-Aldrich, D5758-25M] 
(ie: incubated 30min-overnight at room temp, then autoclaved to remove residual DEPC) 
was used to rinse RNAseZap as needed. 
Calcium Chloride (CaCl2) [Sigma-Aldrich, C1016-100G] was dissolved in 
UltraPure™ DNase/RNase-Free Distilled Water [Invitrogen, 10-977-023] to a stock 
concentration of 5M, and sterilized using a 0.22uM PVDF syringe filter [Cell Treat, 
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229742]. To test various calcium to phosphate ratios during particle synthesis, additional 
stocks were made by diluting 5M CaCl2 to 3.75, 2.5 and 1.25M. Sodium phosphate dibasic 
(Na2HPO4) [Sigma-Aldrich, S0876-100] was dissolved in UltraPure water to 25mM, and 
sterilized using a 0.22uM PVDF syringe filter. The oil phase was made by mixing 
cyclohexane [Sigma-Aldrich, 227048-2L] and Igepal CO-520 [Sigma-Aldrich, 238643-
100G] in a 7/3 ratio until well dissolved to a clear solution.  
All stock lipids were purchased from Avanti Polar Lipids, and dissolved and stored 
in chloroform (CHCl3) [Fisher Scientific, AC42355-0025]. 1,2-dioleoyl-sn-glycero-3-
phosphate (sodium salt) (DOPA) [#840875C], provided as a 25mg/ml chloroform solution, 
was diluted to 20mg/ml. Cholesterol [#700100] and 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) [#850375C] were mixed in a 1:1 molar ratio to a final total lipid 
concentration of 20mM. Powdered 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG2000 or DSPE-
PEG2k) [#880120C] was dissolved to 3mM. 
 
GFP siRNA and DNA 
For initial functional tests, a commercially available siRNA against green 
fluorescent protein (GFP) [Dharmacon, P-002048-01] was used. For quantifying LCaP 
encapsulation and studying cell internalization, the same siRNA was custom ordered from 
Dharmacon with a few modifications: the addition of a CY5 tag on the 5’ end of the sense 
strand and a two base 3’ overhang on both strands. The resulting product had a molecular 
weight of 14,647.7 g/mol and the following sequence:   
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 Sense: 5’-Cy5–GCAAGCUGACCCUGAAGUUCAU–3’ 
 Antisense: 5’–GAACUUCAGGGUCAGGUUGCCG–3’ 
The siRNA, provided as a dried pellet, was spun down and rehydrated using nuclease-free 
Ultrapure water to a stock concentration of 100µM. The stock was aliquoted and stored at 
-20°C until use. For experiments, aliquots were thawed and diluted to a working 
concentration of 20µM.  
For characterization tests that did not require functional siRNA, a DNA mimic was 
used instead. DNA duplex was custom ordered from Integrated DNA Technologies (IDT) 
with the equivalent sequence as the original GFP siRNA duplex I, shown below, and a 
molecular weight of 12,235 g/mol. 
 Sense: 5’–GCAAGCTGACCCTGAAGTTC –3’ 
 Antisense: 5’–GAACTTCAGGGTCAGCTTGC–3’ 
The DNA duplex was re-suspended to 100µM in 1X TE buffer [Epoch, 1160050], stored 
in stock aliquots at -20°C, and used at a working concentration of 20µM.  
 
LCaP Synthesis 
LCaPs were prepared using an oil-in-water emulsion precipitation method, which 
was based on a protocol developed by Li et al. [48, 49]. 20µg siRNA (68.27µl at 20µM) 
was added to a 20mL scintillation vial [Fisher Scientific, 03-337-5] containing 150µl 2.5M 
CaCl2 solution, and mixed via stirring. In a 40mL center drain vial [Sigma Aldrich, 29343-
U], 20µg siRNA was added to 150µl 25mM NaH2PO4 solution. 5mL of the Igepal CO-
520/Cyclohexane oil phase was added to each container and stirred vigorously to form the 
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oil-in-water emulsion. 36.15 µl of 20mg/ml DOPA solution was added to the phosphate 
emulsion, followed by the calcium emulsion. The calcium phosphate was allowed to 
precipitate under stirring for 20min, before being quenched by the addition of 10mL 100% 
ethanol [Fisher Scientific, BP2818-4]. The cores were then centrifuged (for 40min at 4500 
x g) to remove the oil phase and other unincorporated reagents, and washed twice more 
with 10mL ethanol. After the final decanting, the vials were left inverted on Kimwipes 
[Fisher Scientific, 06-666] (for a few minutes) and tapped down periodically to remove 
excess ethanol. 500µl chloroform was added to re-suspend the cores, followed by the 
addition of the outer lipids: 70µl DOPC/Cholesterol (1:1) and 50µl 3mM DSPE-PEG2000. 
The solution was dried to a thin film using a gentle stream of argon or nitrogen [Airgas]. 
To finish the particles, the film was rehydrated with 1mL nuclease-free H2O or 5mM Tris, 
pH 7.4 [Sigma-Aldrich, T2194] pre-warmed to 60°C, the transition temperature (Tm) of the 
lipid with the highest Tm, DSPE-PEG2000. To improve self-assembly of the outer lipids, 
the solution was shaken for 30min – 2hrs at room temperature, then bath sonicated to 
disperse the LCaPs and film. Sonication plus intermittent warming was continued until a 
uniformly translucent (or hazy) solution was reached, with no film left on the sides of the 
vial.  
For “blank/empty” (negative control) particles and earlier studies, ultrapure H2O or 
DNA was used in place of siRNA. For experiments testing Ca/P ratios, 150µl CaCl2 




3.2.2 Characterizing the LCaPs 
DLS and Zeta – Size, Polydispersity, Charge, and Counts 
Particle size was measured using dynamic light scattering (DLS), a commonly used 
technique based on Brownian motion that calculates the size of NPs by shining a laser on 
the sample and measuring the scatter pattern over a set time. Samples were prepared by 
diluting 5-50µl LCaP solution to a final volume of 1mL in 10mM sodium chloride (NaCl) 
[Sigma Aldrich, S7653] in a cuvette [Fisher Scientific, 14-955-129]. The cuvette was 
inserted into the Brookhaven 90Plus [Brookhaven Instruments], and read using the sizing 
software (5 runs, 30sec each, uniform spheres), to obtain information on size, 
polydispersity, and count rate. For zeta potential measurements, an additional 500µl of 
NaCl solution was added to the cuvette for a total volume of 1.5mL. The (Brookhaven) 
electrode [SR-271] was inserted into the cuvette, and the PalsZetasizer software was used 
to measure zeta potential (10 runs, 10 cycles each run).  
 
qNano – Size and Concentration 
For some samples, individual particle counts and concentrations were measured 
using the qNano [Izon Science]. Using tunable resistive pulse sensing (TRPS) technology, 
the qNano converts the resistance of a nanoparticle passing through a stretchable nanopore 
into size and concentration measurements based on polystyrene calibration beads of known 
size and concentration. LCaPs were diluted (1:2 – 1:1000) in PBS and run under pressure 
on a NP200 pore (diameter range 80-400nm) to collect a minimum of 100 counts (and >500 
when possible). 200nm and 400nm standards were run at the same stretch and pressure 
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conditions as the LCaPs for calibration conversions.  
 
Scanning Electron Microscopy 
LCaPs were visualized using scanning electron microscopy (SEM) in order to 
evaluate geometry and size directly. In brief, LCaPs were diluted 1:1000 and 1:10,000 and 
1µl was dried onto carbon mesh wafers. The wafers were taped onto SEM support stubs 
and sputter-coated with gold before being loaded into the microscope.  
 
siRNA Quantification 
LCaP samples were placed into mini dialysis cups [ThermoFisher, 20kDa MWCO] 
and dialyzed in 5mM Tris, pH 7.4 at 4°C for 24hrs to remove unencapsulated siRNA. To 
quantify siRNA, LCaPs were lysed in lysis buffer (5mM Tris + 5mM EDTA + 0.05% 
TritonX-100, pH 7.4) for 10min at 60°C. The siRNA content of the LCaPs were measured 
using the Quant-IT RNA assay kit [ThermoFisher, Q32882] according to the provided 
protocol. In brief, 20µl of lysed sample was added to 180µl of kit buffer in a 96-well plate. 
Samples were then measured at 520/525nm and compared against the kit standards and/or 
a standard calibration curve of the siRNA. As an alternative method to the RNA assay kit, 
LCaPs were loaded with CY5-tagged siRNA, which enabled assessment of loading by 
fluorescence measurements of CY5. 100µl samples were deposited into black/clear bottom 
96-well plates and read on the plate reader at 646/666nm. Calibration curves of CY5-
siRNA were created by serially diluting known concentrations of siRNA, measuring 
fluorescence, and plotting the averaged triplicates against the concentration. 
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3.2.3 Studies of LCaP-mediated delivery and siRNA-induced gene silencing 
Experimental Setup 
The general experimental flow is summarized in Table 1, but in brief, cells were 
grown and seeded onto plates for LCaP treatment. After incubation with LCaPs, cells were 
cultured further to allow time for silencing and knockdown. Cells were then collected for 
analysis via flow cytometry. Experiments had slight variations in length for LCaP 
fabrication, LCaP incubation, and post-incubation steps to optimize conditions.  
 
Day Procedure 
-1 Make LCaPs. 
0 Seed cells. Finish and characterize LCaPs. 
1 Add LCaPs to cells. Incubate 24hrs. 
2 Change media to remove LCaPs. Post-incubate for silencing. 
3-6 Collect cells for flow cytometry analysis. 
Table 1. LCaP experimental timeline for in vitro incubation studies. 
 
Cell Lines and Cell Culture Maintenance 
MDA MB 231 GFP and MDA MB 231, immortalized human breast cancer lines 
that did and did not express GFP, were cultured in Dulbecco's Modification of Eagle's 
Medium (DMEM) [Corning, 15013 CV] supplemented with 10% fetal bovine serum 
[Corning, 35010CV], 1% L-glutamine [200nM, Fisher Scientific,  MT25005CI], and 1% 
penicillin-streptomycin (P/S) [50X, Fisher Scientific, MT30001CI]. The cells were 
maintained through routine passaging in T-25 and T-75 tissue culture flasks [Fisher 
Scientific, 10-126-10, 13-680-65], and stored in a 37°C incubator with 5% CO2. When 
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drawn from frozen stocks, cells were grown and passaged twice before use in experiments. 
During experiments, variations of the culture medium were used as 
annotated/abbreviated/noted below.  
 
Category Shorthand Components/Supplements 
Base media SF DMEM 




D+ DMEM + 10% Fetal Bovine Serum (FBS) 




DMEM + 10% FBS + 1% L-glut + 1% 
penicillin/streptomycin (P/S) 
Table 2. Cell culture media notation and components. 
 
For experiments, cells grown to 70% confluence were seeded onto clear, tissue-culture 
plates [Corning] at least 12hrs before LCaP incubation to give sufficient time for cells to 
adhere. For a 24-well plate, cells were seeded at 5 x 105 cells/well in 0.5mL D++, the 
optimum density according to the manufacturer. For tests using a commercial transfection 
reagent, cells were either plated in D+- (without antibiotic) or media was changed at least 
an hour prior to the experiment to remove antibiotic.  
 
Cell Treatment: LCaP incubation 
Prior to LCaP treatment, LCaP solutions were quantified for siRNA content and 
dosing volumes were adjusted accordingly. Equivalent media volumes were removed from 
wells before adding LCaPs directly to the well. After 24hrs, LCaPs were removed and wells 
were switched to fresh, complete media for post-incubation. 
 
 34 
Cell Treatment: Positive Controls with Commercial Reagents 
For a positive silencing control, the commercial transfection vehicles 
Lipofectamine 2000 [Life Technologies, 11668030] or Dharmafect Transfection Reagent 
4 [ThermoScientific, T-2004-01] were used with DNA and RNA, respectively. Cells were 
switched to antibiotic-free media (D+-) at least 1hr prior to transfection. For a single 24-
well reaction, 2.5µl of 5µM GFP siRNA was mixed with 47.5µl SF DMEM. In another 
tube, 0.5µl Lipofectamine or Dharmafect was mixed with 49.5µl SF DMEM. After 5 
minutes, the two solutions were combined and pipetted to mix, then allowed to incubate 
for 20min at room temperature to complex together. Finally, 400µl D+- was added to the 
mixture for a total volume of 500µl. Media was then removed from the well containing 
cells, and replaced with the Lipofectamine or Dharmafect mixture.  
 
Flow Cytometry Analysis 
Cell Harvesting and Sample Preparation 
After incubation with LCaPs, the cells were maintained in a “post-incubation” stage 
to allow sufficient time for siRNA release, mRNA silencing, and protein knockdown. On 
the appropriate day, cells were collected for analysis via flow cytometry using the 
following protocol.  
Cells were rinsed with cold, sterile phosphate buffered saline (with calcium and 
magnesium) to remove dead cells and any residual LCaPs. Cells were detached using 200µl 
trypsin EDTA, 1X [Fisher Scientific, MT-25-053-CI] at 37°C, quenched with 300µl D+, 
and spun down for 45sec. The supernatant was aspirated and the pellet washed with 500µl 
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cold phosphate buffered solution (PBS) [1X, Boston Bioproducts, R-220], spun down and 
washed again, before being re-suspended in 300µl cold PBS. Cells were analyzed 
immediately and kept protected from light and on ice during flow cytometry. 
 
Data Collection Parameters and Setup 
Flow cytometry data was collected using the FACScalibur (488nm, 603nm lasers) 
[BD Biosciences] and accompanying Cell Quest Pro software. The cell population was 
gated using forward and side scatter (FSC, SSC), and the program set to run each sample 
until 10,000 – 20,000 counts were accumulated within the gate. Fluorescence data was 
analyzed using Cell Quest Pro, FlowJo, or Flowing Software. 
 
3.3 Results and Discussion 
3.3.1 The Effect of the Calcium to Phosphate (Ca/P) ratio on LCaP Physicochemical 
Properties 
LCaP Size Decreases with Increasing Ca/P Ratios 
Similar to most transfection reagents, the positive to negative charge ratio greatly 
affects the nucleic acid condensation and binding efficacy. In the case of the LCaP, these 
charges are derived from the positively charged calcium ions, negatively charged 
phosphate ions, and the negatively charged phosphate backbone of the siRNA (or DNA). 
Stochiometrically, Ca and P only need to be in a 0.5-2.0 ratio (depending on the form) to 
precipitate and entrap the siRNA in the core. Additional Ca ions are available to bind and 
complex additional siRNA. For ease of later comparisons, the siRNA and phosphate  
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content were kept constant while the Ca2+ content was varied. As shown in Table 3, there 
is a definite correlation between Ca/P ratio and size. 
 
 50 Ca/P 100 Ca/P 150 Ca/P 
No siRNA 
100 Ca/P 
Size (nm) 244 ± 4.1 181.0 ± 3.2 165.2 ± 2.2 185.4 ± 3.5 
PDI 0.221 ± 0.010 0.168 ± 0.014 0.207 ± 0.008 0.240 ± 0.97 
Zeta potential (mV) -15.21 ± 0.29 -13.34 ± 1.14 -13.14 ± 0.77 -12.69 ± 1.26 
Count rate (kcps) 47.6 32.5 29.8 33.6 
siRNA conc (ng/µl) 9 9 14 0 
Table 3. siRNA LCaP properties as a function of calcium to phosphate (Ca/P) ratio. 
 
As hypothesized, the mean NP size was inversely related to the Ca/P ratio. For 
LCaPs made with GFP siRNA, the hydrodynamic diameter decreased from 244 ± 4.1nm 
to 165 ± 2.2nm as the Ca/P ratio was increased from 50 to 150. Additionally, the presence 
or absence of siRNA appeared to have a slight effect on size, as demonstrated by comparing 
the LCaPs with Ca/P ratio of 100 made with or without siRNA. The blank LCaPs were 
4.5nm larger, which suggested that the additional charges improved condensation. 
However, it appears the primary size determinant of the LCaP size is the Ca and P content 
itself and that siRNA condensation does not greatly affect diameter. The CaP likely 
facilitates packing through charge shielding, reducing repulsion and enabling stacking, 
more so than by inducing twists into tighter coils (like DNA condensation in histones) [117, 
118]. The charges from the phosphate backbone (versus no extra charges in the no siRNA 
LCaP) are likely contributing to more electrostatic interactions, which pull the molecules 
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into the CaP core and result in a smaller NP. Similarly, by increasing the Ca/P ratio the 
additional Ca charges more strongly attract the phosphate (and negatively charged head 
groups of the inner lipid layer) resulting in a more compact LCaP. 
Size plays an important role in the pharmacokinetics of NPs within the body and 
determines whether NPs will be cleared or have extended circulation. NPs <10nm get 
filtered out by the renal system, NPs 10 – 50nm are removed by biliary clearance, and NPs 
>200nm are generally removed by the reticuloendothelial system (RES) comprised of cells 
and macrophages in the liver, spleen, lymph nodes and circulation [108, 119-122]. NPs 50-
200nm that are able to avoid opsonization have longer circulation times in the body. Cancer 
therapies also utilize the enhanced permeability and retention (EPR) effect to improve 
passive accumulation of NPs in the tumor area. This effect occurs when tumor infiltration 
and rapid angiogenic growth result in chaotic vasculature with abnormally wide 
fenestrations, allowing NPs in the 50-200 range to extravascate through the “leaky vessels” 
into tumor tissue [123]. Poor lymphatic drainage in tumor tissues enables higher NP 
accumulation as well [124]. Overall, except for the Ca/P 50 ratio which is slightly larger, 
the LCaPs fall within the 50-200nm range, and the mean size may be adjusted by varying 
the Ca/P ratio.   
 
Polydispersity 
The polydispersity index is a measure of heterogeneity of a nanoparticle population, 
and ranges from 0 (monodisperse) to 1 (polydisperse). Values under 0.05 are considered 
extremely monodisperse; values above 0.7 are considered heterogeneous or broadly 
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distributed [122]. A PDI below 0.3 is generally considered acceptably homogeneous for 
lipid-based drug delivery carriers [122]. The PDI of the LCaPs ranged from 0.168 to 0.24 
and were consistently under 0.3, demonstrating relatively good uniformity.  
 
Surface Charge – Zeta Potential 
Zeta potential is another characteristic that can greatly influence colloidal stability 
and interactions in vivo. Zeta potential is the net surface charge of the nanoparticle and the 
associated fluid/ions at the NP surface [125, 126]. The LCaPs fabricated had a zeta 
potential range of from -12.69 ± 1.26mV to -15.21 ± 0.29mV. A zeta potential above 
+30mV or -30mV is considered strongly cationic or anionic, and thought to enable to more 
stable NPs due to charge repulsion between particles [127, 128]. NPs with zeta potentials 
between +10mV and -10mV are considered charge neutral, and thought to be less stable 
because of their increased tendency to aggregate [125, 128]. The LCaPs had a slight 
negative charge, which suggests some colloidal stability. There also appeared to be a slight 
trend in decreasing negative charge with increasing Ca, likely because the additional 
positive ions absorb or more tightly bind to the P and siRNA. The siRNA-free LCaPs also 
have a more positive charge than their siRNA-containing counterparts, due to the overall 
reduction in anionic input. Although perhaps not as stable as a more negatively charged 
particle, keeping the LCaPs surface charge closer to neutral may be advantageous, since 
strong surface charges are associated with serum protein adhesion/opsonin binding and 
clearance from the body.  For example, liposomes with a high positive surface charge were 
found to be cleared by the complement pathway and liposomes with a high negative surface 
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charge activated the alternate (lectin) pathway [129]. Neutral liposomes, however, were 
shown not to activate the complement pathway [119], and may promote a longer dwell 
time in vivo.  
Besides circulation and clearance, surface charge can affect cellular internalization. 
Cationic transfection agents are preferred in vitro for their ability to interact with cell 
membranes and promote internalization, but can also result in higher cell toxicity due to 
membrane disruption[128]. Additionally, NPs with a high positive surface charge can lead 
to non-specific cell uptake in the body, preventing delivery of cargo to the intended target. 
Conversely, NPs with a high negative surface charge may be repelled from the cell surface, 
reducing probability of internalization. Data conflicts among which NP charge (positive, 
negative, neutral) is most suitable for in vivo internalization, and is likely confounded by 
differences in NP size and composition. However, it has been suggested that internalization 
of cationic and anionic NPs may be preferentially governed by different mechanisms (i.e. 
caveolin dependent endocytosis vs. clatherin energy dependent endocytosis [121] [14]). 
Overall, a neutral/slightly negative NP will most likely avoid the issues associated with 
cationic reagents and improve specific internalization, especially when paired with a 
peptide targeting moiety.  
 
Count Rate 
Another LCaP property of interest is the unexpected impact of Ca/P ratio on particle 
number. As illustrated by the particle count rate, the lower ratio appears to generate more 
particles compared to the higher ratios. One hypothesis is that in the emulsion phase, the 
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droplets with lower ionic charge did not attract as strongly as those with the higher Ca 
content and took longer to combine with droplets of the opposite charge. Slower droplet 
fusion allowed for retention of more nanoemulsion droplets, which led to more individual 
precipitation reactions and resulted in a larger particle count. This hypothesis was not 
pursued further, but it could be interesting to test this by decreasing the mixing speed or 









LCaP Verification via SEM 
While DLS data is the quickest method to analyze nanoparticle size, visual 
techniques are a useful confirmation of NP synthesis.  LCaPs imaged with SEM are shown 
in Figure 9. 
 
 
Figure 9. SEM image of siRNA LCaPs. 
 
These LCaPs are from a separate synthesis and had a Ca/P ratio of 75. The particles are 
mostly spherical in shape with a relatively smooth surface, but some are slightly oblong 
and appear to have aggregated in pairs. The attachment of the LCaPs may be an artifact of 
the dilution and drying process as opposed to synthesis issues, as other images with more 
concentrated dilutions (1:1000) display individual LCaPs (not pictured because not as in 
focus). Background particulates may be salts from the buffer solution or residual lipids. 
The scale bar of the image shows the LCaPs to be approximately 233-250nm in size, which 
correlates fairly well to the DLS hydrodynamic average of 282.5 ± 9.3nm. The 
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hydrodynamic diameter is usually slightly larger than the actual diameter because it 
assumes association of the surrounding fluid, and the LCaPs were dried and placed into 
vacuum conditions for SEM. Furthermore, the DLS calculates size using equations that 
assume a spherical, monodisperse population, and likely correlates the scatter from the 
larger dimension of the LCaPs into the calculated average. Thus it is not unusual for the 
DLS size to be larger than that found in SEM images. 
 
siRNA Loading 
Encapsulation efficiencies were calculated by dividing the siRNA amount 
(resulting siRNA concentration * total LCaP solution volume) by the total siRNA added to 
the calcium and phosphate solutions. As expected, the highest Ca/P ratio was able to 
encapsulate the greatest amount of siRNA at 14ng/µl (~35% encapsulation efficiency). The 
Ca/P 50 and 100 ratios surprisingly entrapped the same amount of siRNA at 9ng/µl (22% 
efficiency).  
 
3.3.2 In vitro Experiments: LCaP Uptake and GFP Silencing in MDA MB 231 Cells 
Lower Ca/P Ratios Increase LCaP Uptake 
The first in vitro studies were performed in a human breast cancer cell line using 
the LCaPs reported in Table 3. Cells were incubated with LCaPs containing GFP siRNA 
made with varying Ca/P ratios (50-150) for 24hrs, allowed to incubate another 24hrs, and 
then collected for flow cytometry. It was hypothesized that LCaPs with the higher Ca/P 
ratio would be able to deliver more siRNA, resulting in greater percentage reduction in 
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GFP fluorescence. Surprisingly, the opposite was true and cell internalization was inversely 
related with Ca/P ratio. As shown in Figure 10, there was increasing LCaP/siRNA uptake 
with decreasing Ca/P ratio, demonstrated by the populations’ right shift along the x-axis 
(Cy5-siRNA fluorescence).  
 
 
Figure 10. Flow cytometry data monitoring MDA MB 231 GFP cell uptake of Cy5-siRNA-
containing LCaPs made at various Ca/P ratios and the resultant GFP knockdown after a 24hr 
particle incubation and 24hr post-incubation period. Cells were gated on the forward and side 
scatter of the untreated controls. 
 
LCaP 50s had the highest amount of CY5-fluorescence, which was an order of magnitude 
higher than the non-treated controls. Because LCaP volumes were adjusted for equal 
siRNA content, this greater siRNA internalization may be attributed to the higher particle 
numbers in the lower Ca/P ratios (Table 3). However, GFP fluorescence (shown on the y-
axis), did not noticeably decrease as was expected.  It was hypothesized that more time or 
higher siRNA dose was required for siRNA-induced silencing to occur. Therefore 




Longer Incubation Times and Higher LCaP Doses are Required for Silencing Effects 
To determine if longer incubation would improve silencing as a function of dose, 
cells were allowed to culture out to 9 days after treatment with LCaPs. Cells were given 
LCaP (Ca/P 50) containing siRNA at a low (22nM), high (220nM), or no siRNA dose. 
Results from the flow cytometry data are displayed in Figure 11, with the general treatment 





Figure 11. Flow cytometry analysis of MDA MB 231 GFP cells treated with LCaPs  at high 
(220nM), low (22nM), or no siRNA up to 9 days after treatment. a) Representative images for 
each treatment, taken from Day 3 samples b) A representative GFP histogram from Day 4 (left) 
used to calculate GFP knockdown based on median levels of GFP expression (right). 
 
As shown in Figure 11a, the cells treated with the LCaP high dose experienced a notable 
downshift in GFP expression as early as on Day 3. There is still a sub population of cells 
at normal GFP levels, but the majority of the population has decreased GFP expression 
(which may be more apparent in the histogram in Figure 11b). Percent GFP knockdown 
was calculated by averaging the median GFP fluorescence values for each condition, 
normalizing by the average control fluorescence, subtracting from 1, and converting to 
percent. These values were plotted by day in Figure 11b. As shown, the high LCaP dose 
was able to sustain 70% GFP suppression for 6 days, with a slight decrease by Day 9. 
Additionally, the low siRNA dose demonstrated minor knockdown for a sustained 10% 
reduction. Blank LCaPs generally showed no knockdown, but demonstrated a decrease in 
GFP by Day 9. This was more likely because the cells were overconfluent at that point, 
and starting to function less optimally. The control cells also had a lower GFP expression 
on Day 9 compared to Days 3-6, and may have skewed the normalized calculations as the 
total GFP was lower. Thus the data from Day 9 should be taken sparingly, as the GFP 
reduction could be due to decreased overall GFP expression and increased cell 
senescence/death. In another experiment (not shown), cells were treated with siRNA 
delivered via Dharmafect at a concentration of 25 nM for a positive control. Almost 
complete reduction of GFP expression was achieved by Day 3 post-incubation. However, 
only 16% of the original population was viable (within the cell gate) compared to 66.7% 
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of cells treated with LCaPs containing GFP siRNA and 71.8% of the untreated control. 
This is likely due to the toxic nature of the cationic transfection agent.    
Taken all together, these in vitro results are promising and demonstrate that LCaPs 
can successfully deliver siRNA to induce gene silencing. However, it also demonstrates 
that both dose and post-treatment incubation times need to be optimized to maximize (and 
capture) the silencing.  
 
3.4 Limitations, Challenges, and Future Suggestions 
Though a 50-200nm NP range is reported to be better for taking advantage of the 
EPR effect, it has been suggested that penetration through the BBB may be more ideal at 
sub-50nm sizes. One limitation of these LCaP formulations would be their average size, 
particularly for the LCaP 50s which tended to be slightly larger than 200nm. While a blood 
brain tumor barrier (BBTB) with leakier properties than a healthy BBB does exist, its 
integrity depends on the tumor stage and location, and may have limitations on the extent 
of “leakiness” in comparison to the vasculature of other tumor types [130]. Thus some 
suggestions for ways to potentially decrease LCaP size include the following: 
1) Sonication of the oil phases to generate smaller emulsion droplets prior to the 
mixing the Ca and P phases. In theory, smaller droplets should enable formation of 
smaller LCaPs and the smaller “reaction vesicles” should help limit the overall size. 
2) Reduce mixing speed or time during the precipitation incubation step to prevent 




3) Use ultracentrifugation speeds (12,000-20,000xg) to separate or gather the smallest 
particles. Based on liposomal work, liposomes <100nm (and even suggested below 
<200nm) do not pellet easily in solution, requiring 1-2hrs minimum of 
ultracentrifugation for collection. Though the CaP cores should be slightly denser 
than water (~1.1-1.3 g/cm) and in theory pellet out more easily, the population of 
LCaPs collected here appear to exclude potential NPs <100nm. LCaPs in the 40-
50nm range have been reported by Li et al with 20min spins of 10,000 x g. The 
work discussed here does not achieve that speed, in part because of lab equipment 
limitations, but also to remain in the 100-200nm range. 
4) Alter the system by adjusting the siRNA loading while maintaining a constant Ca/P 
ratio. In essence this aim simplified the LCaP charges to two parameters, lumping 
the P and siRNA into one factor. In reality, there are three components 
(Ca/P/siRNA) and there could be more to the interplay of the three than was 
examined.  
  
For future studies, examining the LCaP size, PDI, charge and siRNA 
content/quality after storage at 4°C, 25°C, and 37°C for at least a week or two if not longer 
would be informative with respect to long term stability. Serum stability tests at 37°C could 
also be useful for an approximation of in vivo circulation stability. Attempts were made to 
analyze pH release from pH ranges 4 to 7.4 (to mimic the pH cycle of early stage 
endosomes to lysosomes), but experimental complications prevented a more thorough 
study. Lastly, while CaP precipitation occurred during fabrication, the exact mechanisms 
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and form of CaP that is generated is not understood[131]. Various types of CaP exist, from 
amorphous structures to more crystalline ordering (hydroxyapatite, brushite, octacalcium 
phosphate, etc.), each with its own solubility [41, 132-134] There are thermodynamic 
preferences that guide which phase forms, and they can also transform from one state to 
another[135]. Besides the utility in characterizing dissolution for in vivo release, each 
structure has a different stoichiometry which could be useful to know for the starting inputs 
during LCaP synthesis.  
 
3.5 Conclusions 
In this chapter, LCaPs were successfully fabricated with different Ca/P ratios, 
resulting in particles with diameters ranging from 160-250nm and PDIs around 0.2. It was 
found that increasing the Ca/P ratio decreased the LCaP size and surface charge, increased 
the amount of siRNA loaded, and surprisingly reduced the number of particles generated. 
Furthermore, LCaPs were used to successfully deliver GFP siRNA into GFP-expressing 
MDA MB 231 cells, causing 70% knockdown in GFP expression for up to 6 days. Through 
several in vitro experiments, it was also learned that the LCaP/siRNA dosing and post-
incubation window should be optimized to witness successful knockdown, which may be 
applicable and important for therapeutic dosing. The LCaP protocols generated in this aim 





EVALUATING EGFRVIII AS A THERAPEUTIC GBM TARGET 
The purpose of Aim 2 was to determine the therapeutic effect of silencing 
EGFRvIII as a potential target for GBM treatment. Using the knowledge gained from Aim 
1, LCaPs were used to deliver siRNA against EGFRvIII into cancer lines engineered to 




Epithelial growth factor receptor variant three (EGFRvIII) is a common EGFR 
mutation highly specific to glioblastoma. It comprises up to approximately 35-45% of all 
GBM genetic mutations, making it a fairly prominent target.  This particular mutation 
results in the truncation of the extracellular portion of the receptor (due to in-frame deletion 
of exons 2–7), causing constitutively active signaling, and activation of several oncogenic 
pathways such as increased proliferation, angiogenesis, and invasion (Figure 12). In 
addition, EGFRvIII is thought to contribute to tumor heterogeneity by acting upon EGFR 




Figure 12. Oncogenetic pathways affected by EGFR and EGFRvIII signaling in GBM. [136] 
 
Because of the truncation and lack of an external binding region, EGFRvIII is difficult to 
target with small molecules therapeutics and could benefit from siRNA targeting. 
Furthermore, EGFRvIII seems to play a role in many pathways that enable survival and 
proliferation or inhibit apoptosis. Therefore this chapter evaluates the use of LCaPs for 
delivery of EGFRvIII siRNA to cells expressing the variant, examines the specificity of 




4.2 Materials and Methods 
4.2.1 EGFRvIII LCaP in vitro Experiments 
The parameters explored in Chapter 2 were used to inform experiments with the 
therapeutic target, EGFRvIII. The LCaP fabrication protocol and cell incubation steps used 
previously for the GFP studies were slightly modified, and different quantification methods 
were utilized for this investigation. 
 
siRNA 
Custom siRNA specific to the EGFR variant was ordered based on the sequence 
CUGGAGGAAAAGAAAGGUAAU from Kang et al [137]. The siRNA was modified to 
include a 3’ two base pair (UU) overhang on both strands, with or without CY5 on the 5’ 
end of the sense strand. Similar to the GFP siRNA and DNA duplex, the EGFRvIII siRNA 
was rehydrated with ultrapure water to a storage concentration of 100µM, and diluted to a 
working concentration of 20µM as needed. 
 
Cell Lines 
Multiple cell lines expressing EGFRvIII were used for these experiments. Three rat 
glioblastoma F98 cell lines were provided by the McDonnald Lab at Brigham and 
Women’s Hospital: F98 wild type (“F98” or “F98wt”), F98 cells expressing human EGFR 
(“F98 EGFR”), and F98 cells expressing human EGFRvIII (“F98 EGFRvIII” or “F98 
vIII”). These cells were used in experiments to evaluate the specificity of siRNA-induced 
silencing by comparing changes in human wt EGFR and human EGFRvIII expression 
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levels after incubation with LCaP containing siRNA.  It is important to note that human 
EGFR and EGFRvIII do not have biological functions in the rat F98 cells and thus human 
cells expressing these receptor proteins were used in experiments assessing the impact of 
silencing on cell viability and proliferation. A human glioblastoma U87 MG cell line 
expressing EGFRvIII (“U87 vIII” or “U87 EGFRvIII”) was provided by the Tannous Lab 
at Mass General Hospital. Wild type U87 MG was received from the Torchilin Lab at 
Northeastern University. EGFRvIII does drive signal pathways associated with 
proliferation in the human U87 cells and thus these cells were used to explore the impact 
of inhibiting expression of the variant on cell proliferation and viability.  
 
Experimental Overview 
Variations of the in vitro experiments were repeated with slightly different or 
expanded parameters each time, but in general LCaPs were made using Cy5-EGFRvIII 
siRNA at Ca/P ratios of 50 or 100, along with empty (H2O) or DNA duplex loaded control 
LCaPs. Cells were seeded at 5 x 104 cells/well in 500µl D++ onto 24-well plates the day 
before the experiment. For the experiments, ~5 to 100µl LCaPs (equivalent to ~20-400nM 
siRNA) were added to the appropriate wells in triplicate. For controls, cells were either 
dosed with Dharmafect (25nM siRNA) according to the manufacturer’s protocol 
(described in Chapter 3) or left untreated. After 24hrs, media was changed to fresh D++ and 
cells were allowed to incubate further for silencing to take effect. Cells were harvested 
after 24hrs post-incubation for mRNA analysis or after 48-96hrs for protein quantification, 
described in greater detail in the next section.  
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Viability experiments were performed in parallel, but scaled down for incubations 
conducted in 96-well plates (i.e. 1/5th the volume of media and LCaPs). After 48hrs of post-
incubation, an MTT proliferation assay was performed and MTT absorbance and CY5 
fluorescence for siRNA uptake was measured via a plate reader.  
 
4.2.2 Evaluating EGFRvIII Silencing 
To assess siRNA-induced silencing, RNA quantification through real-time 
polymerase chain reaction (RT-PCR or qPCR) as well as protein quantification via Western 
Blot were used. Both methods of analysis, however, required optimization and validation 
before use.  
 
mRNA Quantification – PCR and qPCR 
In order to confirm if the desired siRNA sequence would work with the obtained 
cell lines, cells first had to be validated for expression of the variant and checked for the 
RNA sequence. To do that, 1) cells were cultured 2) RNA was extracted, 3) RNA was 
converted to cDNA, 4) then amplified using PCR, and 5) the resulting PCR amplicons were 
sequenced by GeneWiz. 
 
Primer and Probe Design for PCR and qPCR 
Polymerase chain reaction, or PCR, is a technique that amplifies DNA through 
repeated cycles of synthesis. It is used to scale up small quantities of DNA for 
quantification or for downstream applications. The reactants—a DNA template, 
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nucleotides (ddNTPs), primers, polymerase—are rotated through optimized temperatures 
to allow primer annealing, enzymatic extension of DNA by polymerases, and the 
unwinding of synthesized strands to provide new templates for replication. Primer design 
is important because it dictates the region that will be amplified and controls the length of 
the resulting amplicons. Primers should be designed to be specific to the DNA sequence, 
avoid self-annealing or dimerization, and to fit the specified temperature window (which 
can be adjusted by primer length and base content).  
Real-time PCR (RT-PCR or qPCR) allows for the quantification of the DNA while 
it is being generated. This technique requires fluorescent probes for quantification and can 
be measured using two general methods: SybrGreen or Taqman probes. SybrGreen is a 
non-specific method which uses a dye that intercalates in the minor groove of double 
stranded DNA and fluoresces more strongly when bound. A TaqMan probe, on the other 
hand, contains both a fluorescent molecule and a quencher attached to an oligo with a 
specific sequence complimentary to the DNA of interest. The probe binds to the DNA and 
gets degraded during DNA elongation, which separates the quencher and fluorophore to 
allow fluorescence. Because of the specificity of the TaqMan probe and of the EGFRvIII 
splice mutation, a probe specific for the mutation site in the variant was designed for 








primer, set 1 
GTCCAGTATTGATCGGGAGAG 
EGFRvIII: 167bp 
EGFR: 968bp EGFRvIII reverse 
primer, set 1 
CACGAGCCGTGATCTGT 
EGFRvIII forward 











GAPDH forward primer ACCACAGTCCATGCCATCAC 
~450-550bp 
depending on cell 
line/variant 
 















Table 4. Primer and probe sequences for PCR and qPCR. 
 
Primers and probes for the EGFRvIII gene were designed using A Plasmid Editor 
(ApE) and IDT’s PrimerQuest Tool. First, the EGFRvIII sequence was inserted into ApE 
and queried for a probe sequence that spanned the splice site of the variant with the 
following criteria: 1) was between 23-30 nucleotides (nt) in length, 2) had a GC content 
between 45-55% (ideally 50%), 3) had a melting temperature (Tm) between 60-70°C, 4) 
started with a G on the 5’ end, and 5) contained no more than 3 poly G’s or poly C’s. Next, 
a few potential probe sequences were entered in the PrimerQuest Tool to find an optimized 
set of qPCR primers for the probe. The search parameters were set so that 1) the primer 
had a Tm between 55-65°C, 35-65% GC content, and was 17-30nt (optimally 60°C, 
50%GC, 22nt), 2) the probe had a Tm between 60-72°C, 40-60% GC content, and was 20-
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30nt (optimally 68°C, 50% GC, 28nt), and 3) the resulting amplicon size fell between 75-
200bp. The set with the highest Tm was chosen because all suggestions were below 60°C. 
Finally, a second set of primers was designed in ApE around the probe such that the two 
Tms did not differ by more than 2°C and they could be combined with the first primer set 
for assay optimization.  
All chosen EGFRvIII probes and primers were custom ordered from IDT. Premade 
GAPDH forward and reverse primers (ReadyMade™ Primers, #51-01-07-12 and #51-01-
07-13) as well as a predesigned GAPDH qPCR assay (probe + primers set, PrimeTime 
qPCR assay ID# Hs.PT.39a.22214836) were also purchased from IDT. Primers and probes 
were resuspended to stock concentration of 100µM in nuclease-free H2O, and diluted to 
working concentrations of 10µM and 5µM, respectively. 
 
Primer Validation and Amplicon Verification 
Primer validation is needed to ensure amplification specificity for the correct target, 
and to optimize the thermocycling parameters. Additionally, PCR was used to confirm that 
the given cell lines expressed the expected fragments and to confirm the gene sequence 
before ordering siRNA and qPCR probes.  
To obtain DNA for primer testing, total RNA was extracted from U87 and U87vIII 
cells then reverse transcribed to cDNA. Cells were grown in T-25 flasks until 70% 
confluent, released using trypsin, and spun down with D+ to form a pellet. The pellet was 
washed with cold PBS and counted to collect approximately 1x106 cells. Using the 
Monarch Total RNA miniprep kit [New England Biolabs, T2010], cells were lysed, treated 
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for genomic DNA, and RNA extracted according to the protocol. Bound RNA was eluted 
in 75µl H2O using the centrifugal method. RNA was quantified on the Nanodrop, then 
reverse transcribed with the SuperScript IV VILO Master Mix sample kit 
[ThermoScientific, 11756010] using 1µg RNA per reaction. Reactions with both the 
suggested positive and negative RT controls were made and thermocycled [PTC-200, MJ 
Research] according to the kit instructions (annealing at 25°C for 10min, reverse 
transcription at 50°C for 10 min, and enzyme inactivation at 85°C for 5 min). 
PCR was then performed using 1µl cDNA template per reaction. PCR reagents 
from New England Biolabs were supplied by the Klapperich lab at Boston University, and 
master mix was made following the NEB Taq Master Mix recipe. For a 1X 50µl reaction, 
the following reagents were mixed together before adding 1µl template: 5µl 10X buffer, 
1µl 10mM dNTPs, 1µl 10µM forward primer, 1µl 10µM reverse primer, 0.25µl 
polymerase, and nuclease free H2O up to 49µl. ReadyMade GAPDH forward and reverse 
primers, as well as EGFRvIII set 2 primers were tested in separate master mixes. Agilent 
SureStart Taq Polyermase was used instead of NEB Taq, and the reaction was 
thermocycled according to the standard SureStart parameters provided (activation at 95°C 
for 10min, 35 cycles of denaturing at 95°C for 40sec, annealing at 53°C (GAPDH) or 51°C 
(EGFRvIII) for 40sec, and extension at 72°C for 40sec, followed by a 10min final 
extension at 72 C and a 4°C hold). 
For visualization, 20µl PCR sample was mixed with 6X loading dye [Biotium, 
41009] and run on 2% agarose gels [Invitrogen, 16500100] (containing 1X SybrSafe 
[ThermoFisher]) in 1X TAE buffer along with a 1kb ladder [Biotium, 41009]. The gels 
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were run at 90mV for 1-1.5hrs or until the bands were at least two thirds down the gel. The 
gel was imaged using the Versadoc [Bio-Rad] on the ethidium bromide (EtBr) setting. The 
EGFRvIII and EGFR bands were cut out and gel purified using the GenCatch Gel 
Extraction Kit [Epoch Life Science, 1260050], and eluted in 30µl elution buffer. Samples 
were quantified on the Nanodrop [ThermoFisher], then sent to GeneWiz for sequencing.  
 
qPCR Experiments 
Primer Efficiency Curves 
For efficiency tests, qPCR was performed with both the EGFR set 2 and GAPDH 
primers, using U87vIII cDNA at 6 different concentrations (serially diluted to 1:100,000). 
qPCR was run using the OneStep Plus Realtime PCR [Applied Biosystems] standard 
comparative Ct settings and the resulting Ct values were averaged and plotted against the 
concentration to obtain the slope. Efficiency was then calculated using the equation: 
Efficiency = -1+10(-1/slope). 
 
qPCR Setup 
qPCR was performed for the in vitro LCaP experiments using the Cells-to-Ct 1-
step  Taqman sample kit [ThermoFisher, A25605]. Eventually the Cells-to-Ct 2-step 
Taqman kit [ThermoFisher, AM1728] was purchased to have better control over the cDNA 
and qPCR steps. The Cells-to-Ct kits are “all-in-one” systems that allow for experimental 
in-plate cell lysis and contains all the reagents needed for lysis, reverse transcription, and 
qPCR. Steps were performed according to the manufacturing protocols. Cell samples were 
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performed in triplicate (biological replicates), and each biological sample was analyzed 
using a qPCR triplicate (technical replicate) due account for variability due to small sample 
volumes. The results were averaged within each group.  
 
Protein Expression – Western Blots 
EGFR and EGFRvIII protein expression was quantified via Western Blot using 
(total protein) whole cell lysates. Cell lines were concurrently analyzed for EGFRvIII 
expression during RNA/DNA sequencing, before use in experiments with LCaPs. 
 
Antibodies 
Monoclonal antibodies against EGFR and EGFRvIII were purchased from Santa 
Cruz (A-10, sc-373746, mouse) and Biorbyt (orb47907, mouse), respectively. Antibody 
against GAPDH [Cell Signaling Technologies, 14C10, rabbit) was provided by Kristyna 
Kotynkova from the Ganem lab, along with secondary HRP-linked antibodies against 
mouse [Cell Signaling, 7076S] and rabbit [Cell Signaling, 7074S]. 
 
In-house Buffers 
Other Western blot materials, buffers, and equipment were also generously 
provided by the Ganem Lab at Boston University, School of Medicine. Specific buffer 
recipes are as follows: Lysis buffer was made by mixing 500µl 1M Tris-HCl pH 8 [Sigma 
Aldrich, T2694], 1ml 20% (SDS) [Amresco, M112], 2ml 50% glycerol [Sigma Aldrich, 
G9012], and 6.5 ml Ultrapure water, followed by 100X Halt Phosphatase and Protease 
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Inhibitor [ThermoFisher, 78440] right before use. 10X PAGE running buffer consisted of 
121.2g Tris, 576g Glycine, 40g SDS dissolved in 10mL ddH2O, and was diluted to 1X for 
use. Semi-dry transfer buffer included 11.64g Tris and 5.86g glycine in 1800mL MilliQ, 
along with 200mL methanol, and was stored at 4°C. TBS-Tween was made by diluting 
10mL 10% Tween in 100mL 10X Tris Buffered Saline, for a 0.1% Tween solution.  
 
Cell Line Validation, siRNA Verification, and Antibody Optimization 
Prior to LCaP experiments, the cell lines were tested to confirm positive or negative 
expression of EGFR and EGFRvIII. EGFRvIII siRNA was also delivered with Dharmafect 
as a positive control. Antibodies were tested to determine signal strength and optimize 
concentrations. 
 
F98 wt, F98 EGFR, and F98 EGFRvIII cells were seeded in duplicate onto 6-well 
plates [CellTreat, 229106] at 1 x 105 cells/well in 2mL D++ and allowed to adhere overnight. 
The following day, one well of each cell type was either incubated with Dharmafect and 
siRNA or left untreated. For the Dharmafect set, the cell media was changed to complete 
media without antibiotic. For each well, 10µl of 5µM EGFRvIII siRNA was diluted in 
190µl DMEM and added to 4µl Dharmafect Reagent 4 diluted in 196µl DMEM, and 
allowed to sit for 20min. 1.6mL D+- was added to the Dharmafect solution, then distributed 
to replace the media in each well. After 24hrs, the media was replaced with fresh D++ and 
cells were allowed to incubate for an additional 48 hours. Wells with untreated cells also 
had media replenished to fresh D++ at the same time as the Dharmafect set.  
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After post-incubation, cells were harvested for Western Blot analysis. All cell 
samples were lysed with 150µL lysis buffer for 1 minute, then scraped vigorously with a J 
hooked scraper [CellTreat, 229306], and collected into 1mL Eppendorf tubes [Fisher 
Scientific, 05-408-129] using a p1000 pipet. Lysates were frozen at -80°C until needed for 
Western blot processing. Once all lysates were ready, they were thawed to room 
temperature, probe tip sonicated (20% amplitude, 20sec) and cooled on ice, then incubated 
with 4X SDS sample buffer at 95°C for 5min. Samples were loaded onto a 7.5% acrylamide 
gel along with ladder [Biorad, Precision Plus Protein Dual Color Standard, 10–250 kD], 
and run at a constant 35mA (starting voltage ~100mV) for 1hr until the loading dye front 
ran off the gel. The proteins and ladder were moved to a membrane using semi-dry transfer; 
a sandwich consisting of two Whatman papers wetted with cold semi-dry transfer buffer, 
an activated PVDF membrane, the gel, and two more pre-wet Whatman papers was inserted 
into the tray of the TransBlot Turbo Transfer System [Biorad] and run on the standard gel 
setting. PVDF membrane was activated by submerging in methanol for 10-30sec and 
rinsing with diH2O (3 x 1min shakes).  
After transfer, the membrane was cut and blocked with 5% milk in TBS-Tween, at 
room temperature for 1hr, then incubated overnight at 4°C with primary (1°) antibody 
diluted 1:500 in 1% milk. Antibody solution was recollected for reuse and stored at -20°C 
with 0.1% sodium azide to prevent bacterial growth. The membrane was washed with TBS-
Tween (4 x 8min), rocked with RHP-linked secondary (2°) antibody diluted 1:5000 in 1% 
milk for 1hr at room temperature, then washed again (5 x 9 min) before being prepared for 
imaging. After removal of excess liquid, the membrane was placed on plastic wrap and 
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developed with ECL or ECL Max reagent [Biorad] for 5 min. Excess reagent was removed, 
and the membrane imaged using the Versadoc on the chemiluminescence, no binning 
setting (100-800 sec, 100 images). A colorimetric image was also taken to confirm the 
ladder position.  
 
Western Blot Parameters for LCaP Experiments 
 Verification of EGFR and EGFRvIII expression by U87 cells was performed 
alongside experiments with Dharmafect and LCaPs. Western blots were performed with 
the protocol above, but using only the EGFRvIII antibody since it was found to bind to 
both EGFR and the variant, as will be discussed in more detail in the analysis.  
 
Cell Viability – MTT Assay 
The MTT Cell Proliferation Assay kit was purchased from ATCC and all steps were 
performed according to manufacturer’s protocols. First, cells were optimized for seeding 
density to find the linear regime for MTT signal. Serial dilutions of cells ranging from 106 
to 103 cells/ml were plated in 100µl D++ in triplicate, and grown for 2-3 days to mimic the 
experimental timeline. A triplicate of 100µl D++ without cells was also plated for a 
background control. 10µl MTT reagent was then incubated with the each well for 2.5hrs 
(or 2-4 hours) at 37°C until purple precipitate was visible under microscope. 100µl MTT 
detergent was used to lyse the cells and release the formazan product. After incubation at 
room temperature in the dark, the absorbance at 570nm was measured via plate reader 
[SpectraMax M5, Molecular Devices] at 4hrs and 24hrs. For analysis, the averaged media 
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background was subtracted from the absorbance values, which were then averaged and 
plotted as a function of cell seeding density. The linear regime was used to determine 
optimal seeding density for subsequent experiments. 
For experiments, cells were seeded at 1 x 104 in 100µl D++ in clear 96-well plates 
and dosed with the appropriate volume of LCaP stock for the desired siRNA 
concentrations. After 24hrs of incubation, LCaPs were replaced with fresh media and post-
incubated for an additional 48hrs before being assayed with the kit, as described above. 
Absorbance values were background subtracted, averaged, then normalized to the 
untreated controls for analysis.  
  
4.3 Results and Discussion 
4.3.1 Validation of EGFRvIII and EGFR Expression in F98 and U87 Cell Lines 
F98 Western Blots 
Prior to nanoparticle testing, the cell lines were checked for expression of the EGFR 
and EGFRvIII proteins using Western blot (and RNA sequencing). Figure 13 shows the 
EGFR and EGFRvIII expression for the F98 wt, EGFR, and EGFRvIII strains, with or 
without EGFRvIII siRNA treatment. The blots were stained with two different antibodies:  
one against EGFR and the other against EGFRvIII. Interestingly, both antibodies display 
the same banding pattern in all paired (cell line) conditions, which suggests that the 
EGFRvIII antibody is not specific to the splice site of the protein variant, but rather to a 





Figure 13. EGFR and EGFRvIII stained Western blots of F98 cell lines.with or without 
Dharmafect EGFRvIII siRNA (25nM) treatment. Antibodies: Santa Cruz A-10 EGFR (1:500), 
Biorbyt orb47907 EGFRvIII (1:500), Cell Signaling 14C10 GAPDH (1:1000) 
 
The expected band sizes for EGFR and EGFRvIII are 170kDa and 145kDa, 
respectively. Surprisingly, there were three distinct bands on the blot rather than just the 
two expected. The topmost thin band present in all the samples was conjectured to be the 
native rat EGFR protein, since it was the sole band present in the wild type strain. It also 
lay within the 150kD and 250kD ladder bands, which fit the expected size for EGFR. Since 
the other two cell lines have been transfected to express the human variant, it is reasonable 
to assume the rat EGFR is not identical and would not necessarily match the banding 
pattern of the human proteins. In both F98 EGFR samples, the second lower band fell 
within the 150kD and 250kD ladder region and was only present in the EGFR strain, and 
therefore most likely correlates to the human EGFR protein. Similarly, the second lower 
band in the F98 EGFRvIII sample fell within the 100kD and 150kD ladder mark, and is 
likely the EGFRvIII protein because it was only present in the untreated but not the 
knockout sample. The internal protein control, GAPDH, showed uniform expression levels 
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across all samples and demonstrated that the lack of bands in the knockout sample was not 
due to a deficiency in protein loading. The absence of a 145kD band in the knockout lane 
also confirmed successful silencing with the siRNA. The siRNA appeared fairly specific 
to the variant, but did seems to have a slight effect on wt EGFR as demonstrated by the 
much fainter native EGFR band in the F98 EGFRvIII knockout sample, as well as the 
reduced thickness and intensity of the human EGFR band in the F98 EGFR knockout 
sample. Overall, it can confidently be confirmed that 1) each cell line expresses the human 
EGFR and EGFRvIII at fairly high levels (shown by the strong band intensity), 2) the 
selected siRNA sequence successfully, strongly and specifically silences EGFRvIII, and 3) 
the EGFRvIII antibody can be used to detect EGFR with a stronger signal than the Santa 
Cruz EGFR antibody at the same dilution. Based on the signal quality, additional antibody 
concentrations were not deemed necessary for optimization. Moving forward, only the 
EGFRvIII antibody was used for staining to conserve reagents and optimize imaging.  
Note: The GAPDH bands (especially those correlating to the Santa Cruz EGFR 
antibody samples) were slightly truncated due to poor membrane cutting. However, the 
second set was a replicate of the first and the same amount of lysate was loaded in each 
lane. 
 
U87 Western Blots 
U87 and U87vIII cell lines were also checked for EGFR and EGFRvIII expression, 




Figure 14. Western blots demonstrating EGFR and EGFRvIII expression in U87wt  and U87 
EGFRvIII cell lines. Reduction of EGFRvIII confirmed by knockdown with Dharmafect with 
20nM EGFRvIII siRNA. Antibodies: Biorbyt orb47907 EGFRvIII (1:500), Cell Signaling 14C10 
GAPDH (1:1000). 
 
Both cell lines included a Dharmafect treatment for the negative expression control, and 
all samples were stained with the EGFRvIII antibody (which binds to both EGFR and 
EGFRvIII). The wildtype U87 cells only displayed one band between 150 and 250kDa, 
which correlated to EGFR. There was no difference in the untreated or Dharmafect treated 
samples, which was as expected, and demonstrated specificity of the siRNA to the variant. 
The U87vIII cells had two bands, an EGFR band in the same location as the U87 line and 
a smaller band below it which fit the expected EGFRvIII size. When treated with 
Dharmafect, the EGFRvIII band showed a reduction in intensity, which confirmed its 
likelihood as the variant. The incomplete knockout could be attributed to a lower treatment 
dose (19nM vs 25nM), or that this cell type is harder to transfect (in general or with this 
particular Dharmafect formulation). However, since there was a reduction in intensity with 




Figure 15. GAPDH, EGFR, and EGFRvIII PCR amplicons from U87 and U87vIII cells for 
sequencing. Samples run on a 2% agarose TAE gel: 1kb ladder (L), U87 or vIII cDNA templates, 
no reverse transcriptase (-RT) cDNA controls no template controls (NTC). GAPDH amplicons at 
453bp (Lanes 2, 3, 4, 7), EGFR band at 1020bp (Lane 2), EGFRvIII bands at 218bp (Lanes 4, 7). 
 
PCR for both EGFRvIII and GAPDH was performed, as shown in Figure 15. For 
both gene sets, the U87 wildtype (wt) and U87vIII variant templates were used. Negative 
controls were also included, and PCR samples were run with a no template H2O control 
(NTC) and cDNA template made with no reverse transcriptase control (-RT). In the 
GAPDH gel, all bands present were just under the 500bp ladder, which corresponded well 
to the expected 453bp GAPDH fragment. No band was present in the NTC lane (Lane 6), 
though faint bands appeared in the -RT lanes (Lanes 3 and 5) which suggest the presence 
of some genomic DNA. However, since the intensity of the wt and vIII templates (Lanes 1 
and 3) was much greater, it was assumed that the genomic contaminants would not greatly 
contribute to measured GAPDH RNA levels during qPCR quantification. And if there were 
some contribution, it would be present at the same levels or ratio amongst all the samples 
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and thus could still be used as a consistent internal control. In the EGFR gel, the negative 
controls (Lanes 3, 5, 6) were all empty which was good. Lane 1 had a single band slightly 
above the 1kb ladder, which was expected for an EGFR fragment from the U87 template. 
The fragments from the U87vIII templates appeared slightly below the 250bp ladder, and 
correlated to the expected 218bp banding. The bands in Lanes 1, 4, 7, and 9 were cut out 
and gel extracted, before being sent off for sequencing. Sequencing results reported that 
the sequences aligned well with the given genomic data, further confirming that both the 
U87 and U87vIII lines express the expected mRNA and work with both the siRNA and 
qPCR probe.  
 
4.3.2 EGFRvIII LCaP Experiments in U87vIII cells 
EGFRvIII Knockdown via LCaPs is Dose and Time Dependent 
Different repeats of knockdown and dosing experiments were performed, with 
some of the more illustrative data presented in Figure 16 and Figure 17. NPs with or 
without siRNA were administered to U87vII cells for 24hrs, and post incubated for 3 days.  
 
 
Figure 16. Western Blots confirming dose-dependent reduction of EGFRvIII via LCaPs. U87vIII 
cells incubated with LCaPs for 24hrs, then post-incubated for 3 days. LCaPs 1 (Ca/P 50) and 3 
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(Ca/P 100) contain EGFRvIII siRNA (100µl = 240nM siRNA), LCaP (Ca/P 50) 2 are blank. 
Untreated U87wt, untreated or Dharmafect treated (DF, 25nM siRNA) U87vIII cells used as 
controls.  
 
As particularly highlighted in Figure 16, siRNA-containing LCaPs 1 and 3 at the highest 
dose (100µl = 240nM) were able achieve protein knockdown, seen by the disappearance 
of the EGFRvIII bands. Blank LCaP 2 at the equivalent dose did not demonstrate the same 
reduction. Additionally, LCaP 1 (Ca/P 50) appeared to have a greater knockdown 
capability at the two higher doses when compared to Dharmafect treatment, and at all doses 
(5-100µl, Lanes 1, 4, 6) when compared to LCaP 3 (Ca/P 100) and the LCaP 2 blanks. This 
is particularly exciting because it confirms that the LCaP is a potent delivery vehicle for 
siRNA at the appropriate concentrations. LCaP 3 (Ca/P100) also displayed some silencing 
as shown with the 100µl dose.  Thus it demonstrates that both LCaPs with different Ca/P 






Figure 17. Western blots of EGFRvIII expression in U87vIII cells treated with varying doses of 
LCaPs, three and four days post-incubation. LCaP 1 (Ca/P 50) and LCaP 3 (Ca/P 100) contain 
EGFRvIII siRNA (100µl = 240nM). LCaP 2 (Ca/P 50) are blank. Untreated U87wt, and untreated 
or Dharmafect treated (DF, 25nM) U87vIII cells used for controls.  
 
In addition, a separate repeat experiment (Figure 17) looked at an expanded dosing 
scheme and extended the post-incubation one day extra. While the results at the highest 
concentrations (100µl = 240nM siRNA) were not as potent as in the previous study and 
resulted in bands not fully absent, there was still an apparent reduction in protein levels 
with increasing LCaP dose for LCaPs 1 and 3 compared to the blank LCaP 2. In addition, 
on the following day, there appeared to be an even greater reduction in band intensity from 
lowest to highest dose, especially with LCaP 3. This reiterates that greater siRNA 
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release/and or siRNA silencing was achievable (or viewable) with a longer post-incubation 
window. It had previously been hypothesized in Chapter 3 that LCaPs with a higher Ca/P 
ratio would bind siRNA more tightly and take longer to release. The results from Day 4 
indicate that this may be true.  It may also suggest that use of the Ca/P 100 (or higher) ratio 
could have a longer and stronger impact on knockdown if (more) siRNA can be 
internalized with a slower release profile, which can lead to more sustained silencing 
(compared to a lower Ca/P ratio). Experiments with even longer time points would be 
needed to verify the sustained effect from LCaP Ca/P 50 and 100 silencing.  
It must be noted that the two highest doses of LCaP 2 have “artificially” low 
expression of EGFRvIII due to improper sample handling that resulted in the collection of 
fewer cells for those lysates. Therefore, a lower concentration of cells and protein was 
loaded compared to all the other samples as can be seen by the reduced GAPDH band 
intensity/width, and thus the results for the two high LCaP 2 doses are not technically 
comparable with the others and should not be taken as representative knockdown.  
 
EGFRvIII Protein Knockdown Results in Decreased Cell Viability 
In addition to the protein analysis via Western blots, the extended dose experiment 
analyzed the effect of the LCaPs and EGFRvIII siRNA on cell viability. MTT assays were 
performed in the equivalent, scaled down 96-well format using the same LCaPs, with the 





Figure 18. MTT viability assay for U87vIII cells treated with different doses of LCaPs, 3 or 4 
days after treatment. Normalized to absorbance of the untreated cells for each day. Solid line at 1 
represents the viability of the control cells; dotted line at 0.75 represents the lowest viability 
resulting from cells treated with blank LCaPs. 
 
As seen in the graph, there is a dose dependent reduction in viability for all LCaPs except 
the 1µl dose (~2.4nM siRNA), which is comparable to the controls. Surprisingly, this 
occurs for all samples (even the blanks) on Day 3 (grey bars), with a trend of lower viability 
with increasing dose, suggesting some impact of the LCaP carrier itself. Perhaps the influx 
of Ca and P as the LCaPs degrade affects cell biology. However, compared to Dharmafect 
treatment which has previously demonstrated up to a 90% reduction in cell viability at 
higher doses, approximately 70% of cells treated with blank LCaPs were viable at the 
highest dose (similar to Chapter 3 Flow data). On Day 4, cells treated with the blank LCaP 
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2 set appeared to recover and approximately 90-95% were viable across all doses.  
When comparing cells treated with LCaP 2 to those administered the siRNA-
containing LCaPs 1 and 3, the cells given siRNA have a viability ranging 10-20% lower 
for the matched blank LCaP dose. Hence this difference should represent the effect of 
siRNA-induced silencing of EGFRvIII on viability. This level is consistent with a 10% 
reduction found in a prior experiment testing Dharmafect delivery of EGFRvIII siRNA 
compared to a control GFP DNA duplex (not shown). Oddly, the Dharmafect controls in 
this experiment do not reflect that decrease in viability (despite demonstrating full protein 
knockdown), but instead are at comparable levels to the untreated controls. This may be 
due to a faster recovery of the cells or that the impact of EGFRvIII siRNA alone is not as 
effective (at reducing viability). Perhaps the assault of CaP plus siRNA in the other 
treatments enabled a more prominent effect on the cell viability. Extending out the window 
of analysis to 5 or 6 days may show further recovery of cells with blank LCaPs and a 
potential sustained viability around 70% for the siRNA LCaP treated cells. While siRNA-
induced silencing was not completely lethal, it should be remembered that these cell lines 
may not have a strong survival dependence on EGFRvIII, as they were engineered to 
express the variant. Therefore, it is possible that primary patient derived tumor cells that 
express EGFRvIII will see more pronounced effects from the silencing of the protein. 
Alternatively, the siRNA-induced silencing of the variant may sensitize the tumor cells to 
a cancer drug or targeted therapy. Overall, these results are indications of successful 




Analysis of mRNA Levels 
qPCR Primer Efficiency 
Efficiency tests for qPCR were performed on the primers to check the amplification 
rates of GAPDH and EGFRvIII at several template concentrations. An efficiency between 
90-110% is desired to ensure that the internal control (GAPDH) can be reliably compared 
to the gene of interest for comparative qPCR. In short, if the amplification rates of the two 
genes greatly differ based on concentration, one cannot be used as a standard for the other. 





Figure 19. qPCR efficiency curves and regression lines for EGFRvIII and GAPDH  primers 
using U87vIII cDNA. 
 
The averaged Ct values were plotted against log concentration, and the slope was used to 
calculate the efficiency coefficient using the equation, Efficiency = -1+10(-1/slope). The 
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efficiencies for EGFRvIII and GAPDH respectively were 90.417 (R2 = 0.997) and 92.207 
(R2 = 0.998). These values were on the lower end but still within the acceptable range, and 
thus the primers were used for the subsequent qPCR tests.  
 
LCaP Experiments qPCR Analysis 
qPCR was performed for several tests alongside earlier Western blots but results 
were contradictory, and both a decrease and increase of EGFRvIII mRNA levels were 
found. Because primers and probes were already designed and evaluated for efficiency, 
and demonstrated successful amplification using a commercial transfection agent, results 
are reported for the benefit of future experiments. In general, Dharmafect treated cells saw 
a 50% reduction in GFP mRNA. Longer time points for Dharmafect treatment also saw 
greater fold change in EGFRvIII mRNA levels, as shown in Figure 20. In another 







Figure 20. Reduction in EGFRvIII mRNA expression in U87vIII cells treated with  Dharmafect 
(25nM siRNA) as a function of post-incubation time (24-72hrs). 
 
While the other negative controls (GFP DNA duplex delivery via Dharmefect and LCaPs) 
appeared to have no significant difference in EGFR mRNA levels compared to the 
untreated cells (Figure 21a), there was considerable variability in the replicates, likely due 
to reduced sample volumes (10-20µl vs 50µl reactions). Figure 21a also suggested an 
increase in mRNA for cells treated with EGFRvIII siRNA rather than a decrease. One 
hypothesis is that LCaP release was slower and siRNA still entrapped in undissolved 
LCaPs were contributing to the signal. Alternatively, siRNA silencing could have created 
a feedback reaction and prompted transcription of mRNA. However, since protein 
expression was shown to be successfully reduced, it seemed contradictory for RNA levels 
to increase. In another case, siRNA LCaPs had slightly higher, but not significantly 
different expression from the untreated controls, while blank LCaPs showed almost 2.25-
fold increased expression (Figure 21b). Some potential explanations included a reactionary 
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step by cells or an effect of the Ca or P on qPCR synthesis, as polymerase levels can be 
sensitive to the environmental ions (i.e. Mg2+). Time points for analysis were at 2 days  
 
 
Figure 21. EGFRvIII mRNA fold-change as a function of LCaP treatment.  normalized to 
untreated U87vIII controls. a) U87vIII cells treated with Dharmafect (DF) with 25nM EGFRvIII 
siRNA or 25nM GFP DNA duplex, LCaPs (100nM siRNA or duplex), with untreated U87 wt and 
vIII controls b) EGFRvIII Fold-change in U87vIII Cells treated with EGFRvIII siRNA via 
Dharmafect (DF, 25nM siRNA), LCaP 2 (Ca/P 50, 240nM siRNA), LCaP 3 (Ca/P 100, 240nM 




post-incubation which is generally sufficient for mRNA reduction. But as seen with the 
Westerns, longer time points may be needed for the LCaP release in particular. 
Additionally, the kit itself may have hindered results. Any background/contaminants from 
the 1-step buffers were carried along from each step, and the lack of control over template 
input led to a switch to a two-step kit, which improved the variability within replicates but 
still led to contradictory data. More traditional RNA extraction techniques (i.e. TRIzol) 
might be more time consuming, but could potentially provide better results. It was 
hypothesized that residual intact LCaPs could have either been releasing more siRNA 
during the cell lysis step, or that the CaP itself could be impacting/increasing enzymatic 
activity during qPCR. A few attempts were made to analyze cell samples spiked with 
siRNA and LCaPs, but results indicated that the spiking did not greatly change or elevate 
qPCR amplification levels. Given that siRNA-induced reduction of protein levels was 
observed in Western blots, further analysis of siRNA-induced silencing was conducted 
with immunoblotting techniques. Protein levels are also considered a better indicator of 
silencing than mRNA levels, especially as the protein is more likely to participate in 
downstream signaling cascades and cellular pathways and have a biological effect on the 
cell.  
 
4.4 Limitations, Challenges, and Future Suggestions 
There is some inherent batch to batch variability which appears to affect the LCaP 
siRNA delivery and release, even when administered at the same dose. This shift in the 
optimal release time can affect in vitro studies as well as in vivo therapeutic delivery 
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windows, especially if concurrent or sequential treatments will be used. Thus it is necessary 
to find ways to minimize that variability (e.g. same reagent stocks, automated mixing and 
handling) or develop ways to easily test every batch to predict in vitro/vivo responses (e.g., 
release kinetics). Furthermore, reliable scalability may be a limiting factor for clinical 
production and optimization should be considered.  
Additionally, these studies only assayed for changes in protein levels and cell 
viability in 3-4 day windows, but still suggest (as in Chapter 3) that longer time frames 
would be beneficially informative. In particular, exploring the release rates for LCaPs with 
Ca/P ratios of 100 vs 50 may show a more sustained release profile and silencing that could 
be harnessed for clinical treatment. Based on the MTT results, it may also be interesting to 
study the impact of siRNA treatments combined with another agent (i.e., cytotoxic drug, 
inhibitor, other siRNA targets). This may be especially beneficial if they affect related but 
orthogonal pathways, such as those used in combination therapies or chemotherapy drug 
cocktails.  
Finally, though mRNA levels are not necessarily the best indicator of the 
therapeutic effect of silencing, more qPCR work could be useful to tease out the apparent 
upregulation of expression caused by the LCaPs. While it seems to have limited impact on 
inhibition of protein expression, it would be useful to understand if LCaPs do have some 
adverse or reverse effect on mRNA expression or if the CaP affects DNA polymerization 





In this chapter various F98 and U87 cell lines were validated for expression of 
EGFR and EGFRvIII. Furthermore, LCaPS at ~250nM siRNA doses achieved almost 
complete knockdown of EGFRvIII. Longer time frames (3–4 days minimum) are required 
to see the silencing effect, but there also appears to be potential for more sustained silencing 
via slower siRNA release using LCaPs with Ca/P 100 vs 50 ratios. The protein knockdown 
resulted in up to 38% reduction in cell viability levels, which may actually be attributed to 
both the siRNA and impact of CaP dissolution in the cell. However, 10–20% of the 
reduction in viability can be attributed to siRNA-induced silencing and not the carrier. The 
increased impact, however, suggests that a combination therapy may be more effective for 
human patients in eliminating cells expressing EGFRvII. These results in the U87 
EGFRvIII cell line make for promising clinical utility, especially if patient specific cells 




ESTABLISHING AN IN VITRO MODEL OF THE HUMAN BBB AND 
EVALUATING ANGIOPEP-MEDIATED TRANCYSTOSIS OF LCAPS 
This chapter focuses on Aim 3 which was to engineer a surface-modified LCaP for 
RMT-mediated transcytosis of nanoparticles across the BBB. In particular, the ligand 
Angiopep-2, which is a receptor for the low density lipid receptor protein 1 (LRP1) was 
studied. Here, the surface density of LRP1 was analyzed for its impact on the penetration 
and accumulation of NPs across a Transwell model of a BBB. In addition, human induced 
pluripotent stem cells (iPSCs) were differentiated into brain microvascular endothelial cells 
(BMECs) for use in the BBB model to more closely mimic the human BBB. Barrier 
tightness was assessed by transendothelial resistance (TEER) and dextran permeability, 
and later cancer cells were incorporated into the model to determine if ANG-LCaPs 
accumulate at appreciable levels for potent silencing of a target oncoprotein. This was one 
of the first human iPSC BMEC BBB models to be used to analyze ANG-assisted 
nanoparticle transcytosis. The utilization of a BBB model that uses human derived cells in 
both the BBB and tumor layers should be more representative of the physiological 
environment and may better reflect in vivo performance. 
 
5.1 Background 
5.1.1 LRP1 and Angiopep-2 
Low density lipoprotein receptor 1 (LRP1) is one of the few transmembrane 
receptors that plays an important part in the transport of large hydrophilic molecules (such 
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as cholesterol, aprotinin, amyloids) through the BBB, and has an active role in intracellular 
signaling, lipid homeostasis, and clearance of apoptotic cells [2, 138-140]. In addition to 
being expressed by brain endothelial cells, it is overexpressed in gliomas and brain 
metastases [2, 86, 90, 141]. 
Angiopep-2 (ANG) is 19-mer peptide derived from the Kunitz domain of aprotinin 
that was found to bind to LRP1 and facilitate increased transport across the BBB via 
receptor mediated transcytosis [90, 91]. Several studies have used ANG used to enhance 
BBB delivery of cargo or NPs conjugated to the peptide [78, 92, 94, 96-98, 142]. Thus 
many researchers are exploring its potential as a “Trojan horse” to increase penetration 
across the BBB for delivery of therapeutic molecules [9, 84, 85, 143]. 
 
5.1.2 A Transwell BBB model 
A classic and easy to use model is the Transwell (TW) model. Depicted in Figure 
22, the TW consists of a well and an insert containing a semi-permeable membrane that 
divides the well into two chambers while allowing the flow of fluid and solutes from one 
side to the other. Membranes of various pore sizes (0.2µm – 5.0µm) and materials (PET, 
PFTE, etc.) can be chosen. Cells can be grown directly on one or both sides of the 
membrane to mimic a BBB layer. Cells can also be grown in the bottom well to mimic 





Figure 22. Schematic of a Transwell BBB model.  
 
A barrier established on the TW membrane significantly reduces passive diffusion 
of ions, molecules, and solutes, thus reducing the permeability of the interface.  A common 
method for assaying BBB permeability is transendothelial electrical resistance (TEER), 
which is a measure of barrier impedance to ion transport across the interface. For reference, 
the human BBB is thought to have a TEER of >2000Ω∙cm2 [106, 126]. Animal studies 
report the BBB of rat and frog brains to be in the 1000-2000 Ω∙cm2 range [109, 110]. 
However, it is generally accepted that a BBB model with minimum TEER values of 150-
200 Ω∙cm2 can be used for drug transport studies [126, 127, 144, 145]. This has served as 
a guide for the design of BBB models for screening potential brain therapeutics.  
Cell type plays a big role in determining the “tightness” of the BBB model, and can 
range from primary animal brain ECs, immortalized cells lines, or differentiated stem cells. 
Most BBB models using primary animal endothelial cells achieve TEER between 300 - 
900 Ω∙cm2 levels, while models employing immortalized endothelial cells generally have 
TEER in the 10-300Ω∙cm2 range [110, 146]. While primary cells generate higher TEER 
compared to immortalized cell lines, they are difficult to acquire, purify, and propagate in 
vitro. Currently, human derived BMECS are gaining excitement for their ability to express 
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tight junction proteins and reach physiological levels of tightness [109, 113]. 
 
Human Derived Brain Endothelial Cells (BMECs) 
The Shusta Lab published a landmark paper in 2012, describing a protocol to derive 
primary human brain microvascular endothelial cells (BMEC) from human induced 
pluripotent stem cells (iPSCs) for use in a BBB model [112]. The resulting BMECs highly 
expressed tight junction proteins and were able to achieve TEER values exceeding 
200Ω∙cm2 in monoculture and up to ~1500Ω∙cm2 when co-cultured with astrocytes. 
Sucrose permeability at the higher TEER values was reported to be 5.6x10-7cm/sec. 
Optimized cell seeding density and incorporation of retinoic acid in the protocol has led to 
BBB models composed of only BMECs with TEER values up to 2000 – 3000Ω∙cm2 [113, 
114] This has generated a lot of excitement in the field because it can more accurately 
reflect a human physiological barrier and the cell source can be generated when needed.  
The protocol consists of 4 stages: 1) the culture of iPSCs and their singularized 
seeding, 2) density optimization and the start of iPSC differentiation into endothelial and 
neuro-progenitor cells, 3) expansion of the BMEC population, and 4) selection of the 
BMECs onto TWs or tissue culture plates. With optimal seeding, the model BBB can 
reliably achieve high TEER with peak values 2 days after TW selection. However, BBB 
models composed of BMECs in monoculture are not robust and barrier permeability 
increases shortly after peaking. The addition of astrocytes or pericytes can sustain a tighter 
barrier for longer periods but does increase the complexity of the culture protocol (i.e. 
various culture media and growth factors are required for establishment) [67, 70, 109, 111].  
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The co-culture of the neuro-progenitors and endothelial cells is thought to mimic the 
environment of the early BBB and promote the formation of more accurate models of the 
BBB [68, 113]. 
While TEER is a strong indicator for tightness—higher TEER equates to a tighter 
barrier, and vice versa—it cannot distinguish between resistance caused by tight junctions 
or other physiologic properties. It is inversely related to permeability, but this relationship 
is not linear and depends on the solute and environmental conditions. Therefore, another 
useful measurement is the physical permeability of a small molecule, such as dextran or 
sucrose. These small molecules (often radio- or dye-labeled) are added to one side of the 
BBB (e.g.: top of the Transwell), and the penetration and accumulation on the opposite 
side is measured over time. The flux or rate of penetration can be used to calculate a 
permeability coefficient, which is further detailed in the methods section below.  
 
5.2 Materials and Methods 
5.2.1 Synthesis of a Lipid-Angiopep Conjugate 
Angiopep-2 was custom purchased from Tufts University Core Facility. The 
peptide sequence is TFFYGGSRGKRNNFKTEEY with a molecular weight of 2420Da. 
To incorporate the peptide into LCaPs for transcytosis experiments, ANG was covalently 
coupled to DSPE-PEG3400-maleimide (DSPE-PEG3.4k-mal) [Nanocs, PG2-DSML-3k] 





Figure 23. Reaction scheme for Angiopep-2 conjugation to DSPE-PEG3.4k-mal. 
 
PBS (or Tris) with 5mM EDTA, pH6.5-7.5, was degassed for 30min-2hrs under 
vacuum stirring. Angiopep was dissolved in degassed buffer to a concentration between 2-
10mg/ml. In a separate vial, DSEP-PEG3.4k-mal was dissolved in buffer warmed to 60°C 
to a concentration ranging from 0.04 – 0.16nM to generate micelles for conjugation. If lipid 
did not go into solution completely, rounds of gentle sonication and heating were applied 
until a clear solution was generated. A sample of the lipid solution was measured via DLS 
to confirm the presence of micelles. Micelle solution was then added to the peptide solution 
in a molar ratio of 1:1.1 (excess peptide) under stirring, and left to conjugate for 24hrs at 
room temperature. The following day, free peptide and salts were removed using three 
rounds of centrifugal filtration [20kDa MWCO Amicon filter] or via dialysis [20 -100kDa 
MWCO cellulose tubing, Spectrum Labs] in distilled water for 24hrs. Purified conjugate 
was then frozen at -80°C overnight and lyophilized for 2 to 3 days until a dry powder. For 
experiments with LCaPS, conjugate was resuspended in chloroform before addition to the 
NPs. 
The conjugation was checked using thin layer chromatography. In brief, the 
conjugate along with ANG and DSPE-PEG3.4k-maleimide controls were spotted and dried 
onto a silica-coated glass chromatography plate [EMD Millipore, 1.15327.0001]. Samples 
were eluted up the plate using a mixture of 80:20 chloroform:methanol. UV detection was 
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used before and after sample runs to identify protein spots and fluorescent molecules. Then 
the plate was sequentially stained to check for movement and co-localization of the peptide 
and lipid to confirm conjugation. Stains included ninhydrin [Sigma Aldrich, 17975-
100ML] with 110°C heating for detection of amino acids/amines, followed by Dragendorff 
reagent [Sigma Aldrich, 44578-100ML-F] and/or molybdenum blue [Sigma Aldrich, 
M1942-100ML] for detection of phosphate/phospholipids. 
 
5.2.2 Fabricating LCaPs with ANG 
To test ANG transcytosis capabilities, LCaPs were made as reported in Chapters 3 
and 4, but with adjustments to the lipids in the outer shell. 1 mol% of the DSPE-PEG2k 
was substituted with either 1% 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (DPPE-rhodamine) [Avanti, 810158] or 1% 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) 
(DSPE-NBD) [Avanti, 810141] to fluorescently track the NPs across the transwell. In 
addition, DSPE-PEG2k was substituted with the equivalent molar amount (0-5%) of 
DSPE-PEG3.4k-ANG when required. 
 
5.2.3 The Transwell BBB Model 
Differentiating iPSCs into BMECs 
For the BBB model, human induced pluripotent stem cells (iPSCs) were 
differentiated into brain endothelial cells using the protocol outlined by Stebbins et al 
[113]. iMR90-C4 iPSCs were purchased from WiCell and used at passage numbers 
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between 46-49. By adjusting the culture medium, stem cells were cultured in 4 phases: 1) 
a growth phase to expand and seed the cell population, 2) a differentiation phase, 3) an 
expansion phase of the endothelial population, and 4) a selection phase between the 
resulting endothelial and neural progenitor cells. A depiction is illustrated in  
Figure 24. The full protocol can be found in the paper [113], but in brief, cells were 
grown on Matrigel-coated [Corning, 356230] 6-well plates [Costar, 07-200-80] in mTeSR1 
[Stem Cell Technologies, 05850] to 80% confluency, before being split and seeded in 6-
well plates at 8.5 x 104 cells/well for the start of differentiation. Cells were grown for 
approximately 3 days to a density of 3 x 105 cells/well. Media was then changed to 
unconditioned media (UM) for 5 days to induce differentiation. On Day 6, the media was 
switched to endothelial cell (EC) media to drive BMEC differentiation. On Day 8, cells 
were reseeded onto collagen IV/fibronectin (col/FN) coated TWs [12 or 24-well well, 
0.4µM or 3.0µM pore, PET membranes; Corning 3470 and 3472] for BMEC selection and 
cultured with retinoic acid (RA) to promote tight junction formation. Experiments were 





Figure 24. The process for differentiating human iPSCs into BMECs. 
 
To generate BMEC stocks, cells were frozen down on D8 in freezing media (60% 
EC media + 10% dimethyl sulfoxide [Sigma Aldrich] + 30% FBS, protocol by Wilson et 
al [147]), and stored in liquid nitrogen for later use. For experiments, cells were thawed 
and seeded onto col/FN coated TWs at 2-4 times the suggested concentration to account 
for cell death. The thawed BMECS were grown according to the Day 8 to Day 10 protocol, 
and used the same media as fresh BMECS with the additional supplement of 10µM ROCK 
inhibitor [Y-27632 (hydrochloride), Cayman Chemical Company, 10005583] on Days 8 
and 9 to promote attachment. 
Immortalized rat brain endothelial cells (bEND.3) were also used in TWs to 
compare BBB permeability. Cells were cultured in DMEM/Ham’s F-12 (50/50) media 
[Corning, 10-092-CV]. For BBB experiments, cells were seeded onto col/FN TWs at 2.5-




Confirming BMEC Expression of LRP1 
LRP1 expression of the differentiated BMECs was validated via Western blot using 
the same protocol described in Chapter 4. The following antibodies against LRP1 were 
tested for signal optimization: Santa Cruz 5A6, Santa Cruz 8G1, Abcam EPR3724, and 
Cell Signaling #64099.  
To generate cell lysates, iPSCs were grown according to the protocol above, but 
were plated onto col/FN coated 6-well plates instead of TWs on Day 8. On Day 10, cells 
were incubated with 150µl Western Blot lysis buffer and collected for analysis. In addition, 
a few cell lines known to express or not express LRP1 were used for controls. These 
included the breast cancer line MDA MB 468, as well as the MDA MB 231 and U87-MG 
cell lines. Note: bEND.3 cells were not analyzed by Western blot for LRP1, but work by 
previous lab members utilized this cell line for NP BBB transcytosis and confirmed ANG 
binding [142]. Work in literature have also confirmed the expression LRP1 by bEND.3 
cells [92].  
 
Characterizing the BMEC BBB 
TEER Measurements 
TEER measurements were made using the EVOM2 [World Precision Instruments]. 
The STX2 electrode was inserted into the top and bottom TW chambers and ohmic 
resistance was recorded. Measurements were then converted to final TEER values by 
subtracting the background resistance of blank TWs, and multiplying by the surface area 
(1.1cm2 for 12-well TWs, 0.33cm2 for 24-well TWs). TEER was measured starting on Day 
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9 and throughout the experiment. 
 
Permeability Studies with Dextran 
Permeability studies were performed using fluorescein isothiocyanate dextran, 
4000Da (FITC-dextran4k) [Sigma, FD4-100MG]. FITC-dextran4k was dissolved in media 
(1% platelet-poor plasma-derived serum (PDS) [Life Technologies, AAJ64483AE] + 
human endothelial serum free media (heSFM) [Invitrogen, 11111-044]) to a concentration 
of 10µM. The dextran solution was then added to the top of the TW (replacing the media), 
and 150µl aliquots were taken from the bottom chamber and replaced with fresh media 
every 15min for at least 1 hr. At the end of the time course, 150µl was taken from the top 
chamber as well. Blank TWs without cells were used for comparison for the permeability 
coefficient calculations. Fluorescence of the aliquots was measured on a plate reader, and 
permeability coefficients were calculated according to the provided protocol [113]. In brief, 
fluorescence values were corrected for dilution at each time point, then background signal 
from media was subtracted out. The clearance volume was calculated using the equation 
Clearance volume = (VB ⁄ (SB,t))/(ST,end) 
where VB is the volume of bottom chamber (1500 µl), SB,t is the corrected signal of bottom 
chamber at time, ST,end is the signal of top chamber at the end of the test (ie: 60 min). The 
slope of the clearance volume versus time was used to calculate the permeability coefficient 
(Pe) by the formulas [26] 
1/Pe = 1/mc – 1/mf 
where mc and mf are the clearance slopes from the cell culture and blank filter TWs, and   
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Pe (cm/min) = [(1/(1/Pe))/1000]/Area 
(or divided by 60 for cm/sec) 
 
Assessing the Effect of ANG density on LCaP BBB Penetration  
ANG-LCaPs for BMEC Penetration and GFP Knockdown  
BMECs were differentiated and plated onto 12-well TWs as described above. On 
Day 9, MDA MB 231 GFP cells were seeded onto separate 12-well tissue culture plates at 
5 x 104cells/well in 500µl D++. On Day 10, media in the GFP wells was changed to BMEC 
media (1500µl 1% PDS + heSFM) and TWs were grouped according to TEER levels and 
redistributed into the GFP cell plates with 500µl fresh 1% PDS + heSFM. 0% or 5% ANG-
LCaPs containing GFP siRNA were added on the top of the TWs. At 4hrs, 150µl aliquots 
were taken from the bottom chamber and TWs were moved to new wells with fresh 1% 
PDS + heSFM to incubate for 20hrs more. Media in the GFP wells were exchanged for 
500µl D++ and cells were incubated for 3 days before analyzing GFP expression using flow 
cytometry. Values were averaged and normalized to the untreated controls. At 24hrs, 150µl 
aliquots were taken from the top and bottom TW chambers and quantified on a plate reader 
along with the 4hr aliquots. 
 
ANG Density Experiments 
To further explore the effect of ANG on LCaP penetration, blank NBD-labeled 
LCaPs were fabricated with 0, 1.5, or 5% ANG. 50µl or 200µl of LCaP solution was added 
to the top of TWs seeded with BMECS after removal of equivalent amounts of media. 
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100µl of LCaP solution was also added to col/FN coated, blank TWs (e.g. no cells) for 
comparison. 150µl aliquots were taken from the bottom chamber and replaced with fresh 
media every 15min for the first hour, then again at 2, 4, 18, and 24hrs. At 24hrs, 150µl 
aliquots were also taken from the top chamber. 100µl of each aliquot was added to a 96-
well black/clear bottom plate and read on the plate reader. Fluorescence values were 
adjusted for dilution and averaged by condition. TEER of the BBB was also measured 
before the experiment and at each time point starting from 1hr.  
 
Confocal Microscopy of BMEC layers 
The BMEC model was assessed for LCaP trafficking via confocal microscopy. 
BMECs were seeded onto 24-well TWs and incubated for 4hrs with rhodamine-tagged 
LCaPs containing CY5-GFP-siRNA and decorated with 0% or 5% ANG.  
For confocal microscopy, BMEC TW membrane inserts were rinsed in cold PBS, 
fixed with 4% paraformaldehyde [ThermoFisher] for 10min at RT, rinsed 3X with PBS, 
then stained with 4′,6-diamidino-2-phenylindole (DAPI) [ThermoFisher] diluted 1:5000 in 
PBS for 5mins before a final rinse in PBS. Membranes were cut from the plastic insert 
using a scalpel, then mounted onto glass slides. Confocal images were taken on the 




5.3 Results and Discussion 
5.3.1 Characterizing the iPSC BMECs and BBB Model 
Differentiated Human Brain Endothelial Cells Express LRP1 
Because LRP1 is required for ANG binding, it was important to confirm if the 
differentiated BMECs expressed the receptor. Western blot analysis of Day 10 BMECs 
demonstrated the presence of LRP1 (85kDa) in the expected 75-100kDa size range, as 
shown in Figure 25. Based on band intensity, the iPSC BMECs expressed LRP1 at strongly 
detectable quantities. This matched the positive control of the U87-MG lysates, which was 
expected to express high levels of LRP1. Surprisingly, the MDA MB 231 cells which are 
 
 
Figure 25. Western Blots of Day 10 BMEC lysates using different LRP1 antibodies  at varying 
concentrations. Cell line lysates were used as positive (U87-MG, MDA MB 231) and negative 
(MDA MB 468) LRP1 controls. 
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also reported to express LRP1 did not express high levels of LRP1, as demonstrated by the 
faint bands. This may be beneficial for in vivo specificity. If LRP1 receptor expression in 
BMECs and gliomas is significantly higher than in other tissue types, it will enable BBB 
targeting as well as internalization by glioma cells. GAPDH internal controls confirmed 
relatively even loading across all samples.  
It should be noted for future use that the EPR3724 antibody displayed very sensitive 
and specific signal, even at a 20,000-fold dilution. The Cell Signaling antibody also showed 
faint bands, reconfirming the banding pattern for the LRP1. If used in the future, higher 
concentrations of the Cell Signaling antibody are recommended for improving detection. 
Use of the Santa Cruz (LRP1) antibodies is not recommended as they showed no binding 
specificity and very poor signal in the same lysates, despite being used at higher 
concentrations (1:100).  
 
FITC-dextran Permeability and TEER of the BMEC BBB 
The model barrier was characterized by measuring TEER and assessing its 
permeability to FITC-dextran4k. During differentiation, cells were grown with or without 
retinoic acid (RA) from Days 6-8, in order to see if high TEER “tight” and low TEER 
“leaky” barriers could be formed. It also provided a good starting point to evaluate 
differences in BMEC BBB permeability based on TEER measurements. The resulting time 





Figure 26. Permeability time course for iPSC BMECs grown with (left) or  without (right) 
retinoic acid (RA) on Day 6-8. Permeability coefficients reported under each graph. Blank control 
(ctrl) Transwells included for Pe calculations.  
 
The average TEER during experiments was 235 ± 158 Ω∙cm2 and 6.0 ± 3.4 Ω∙cm2 
for the RA and no RA conditions, respectively. As might be expected, the cells grown with 
RA (which promotes tight junction formation) produced tighter barriers, which was also 
represented by the lower average slope of FITC-dextran accumulation and smaller 
permeability coefficient (Pe) of 4.181 x 10-6cm/sec. The barriers made with cells grown 
without RA had an average Pe of 7.644 x 10-5 cm/sec, which is about 18 times larger than 
that of the cells with RA. These values are approximately within an order of magnitude of 
that reported by Stebbins et al. for sodium fluorescein permeability (<1 x 10-6cm/sec) when 
TEER is above 2000Ω∙cm2. Given that sodium fluorescein is a very small molecule 
(376.27Da) and 2000Ω∙cm2 is approaching physiologically relevant levels of BBB TEER, 
it can be interpreted that Pe values below 1 x 10-6cm/sec are considered “impermeable” for 
BBBs created with these cells. Using that definition, a value of 4.181 x 10-6cm/sec is 
relatively “tight” or less permeable, especially considering that the size of the LCaPs will 
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be much greater than that of dextran4k used in this study. 
The same permeability test was repeated using bEND.3 cells in 24-well TWs. The 
resulting TEER and Pe values were 5.55 ± 2.65 Ω∙cm2 (n=3) and 1.197 x 10-5cm/sec. The 
TEER for the bEND.3 cells was very similar to that for BMECs differentiated without RA, 
and the associated permeability was ~6 times larger. It could be hypothesized that the 
permeability of the same molecule through the bEND.3 layer would be close to or greater 
than that of the BMECs, given reports that the bEND.3 cells do not form as tight of barriers 
as other cell sources and that the differentiated BMECs are known to express several tight 
junction proteins [81, 105, 109]. These numbers suggest that using a consistent solute (e.g. 
FITC-dextran4k) for permeability studies will generally produce consistent results. It is 
reassuring that the permeability coefficients with similar TEER are not drastically different 
(ie: >1 order of magnitude) and FITC-dextran permeability could potentially be used as a 
benchmark or standard between different BMEC batches, experiments, or cell lines.  
Because assessing the relationship between TEER and solute permeability is not 
trivial and is dependent on several factors (model/cell type, multiple repeats, precise 
control over barriers, etc.), there are only a few thorough studies reported in literature [127, 
144, 145]. It has been reported that the general relationship between TEER and 
permeability is non-linear and most closely resembles exponential decay [127]. At low 
TEER values the permeability increases rapidly, while at high TEER values there is 
reduced flux through the endothelial barrier. For dextran-4k, transport across a monolayer 
BBB composed of primary bovine BMECs and primary rat astrocytes was reported to be 
independent of TEER above 121 Ω∙cm2 [144]. For other solutes (mannitol, inulin), 
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transport across frog kidney epithelial A6 cell monolayers was independent of TEER above 
200Ω∙cm2 [127]. Therefore, above this threshold TEER, the BBB is essentially 
“impermeable” to those solutes. Using these examples and the dextran permeability results 
from the iPSC BMEC model, BBB layers with TEER >250 Ω∙cm2 was set as the threshold 
for dextran and LCaP “impermeability”. 
 
5.3.2 ANG-LCaP Experiments in the BMEC BBB Model 
Over the course of the LCaP experiments using differentiated BMECs, there was 
considerable variation in barrier tightness and inconsistency in achieving TEER as high as 
the reported levels. Based on the 250 Ω∙cm2 TEER threshold, experiments were stratified 
by “high” and “low” TEER groups to better compare permeability or transcytosis efficacy 
across testing conditions. For each experiment, the average TEER was arranged to be near 
equal across all testing conditions. Additionally, when possible, TWs were distributed so 
that TWs within each treatment condition had TWs of the near equivalent TEER to those 
in the other conditions (e.g. 40, 100, 120Ω∙cm2 in one set; 42, 95, 128Ω∙cm2 in the other), 
and the TW set with the highest average TEER was used for studies on ANG-LCaPs 
penetration. This way accumulation could be more confidently attributed to the treatment 
and not due to lower TEER. While not ideal, the results are still informative and in principle 
the variation could be reduced by increasing sample numbers and adding experimental 
repeats (when not limited by cells and materials). The inconsistency also illustrates the 
difficulty in designing and creating BBB models that can mimic the human BBB 
environment reproducibly and reliably. Furthermore, there is utility in testing BBBs with 
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“low” TEER using human derived BMECS, because it can simulate an extremely 
progressed tumor stage with a highly affected BBTB. 
 
ANG-LCaP Penetration Experiment for GFP knockdown 
ANG Potentially Improves LCaP Accumulation 
 LCaPs with (5%) or without (0%) ANG were added to the apical side of the BBB 
model and LCaP accumulation on the basolateral side was assessed at 4 and 24hrs. “High” 
and “low” TEER TW BBBs were evaluated. As shown in Figure 27, LCaPs with ANG 
appeared to have greater accumulation compared to LCaPs without ANG, especially across 
the  tighter  BBBs.  At  4hrs,  the  accumulation  for  LCaPs  with  or  without  ANG  was  
  
 
Figure 27. Basolateral accumulation of LCaPs with or without ANG, through low and high 
TEER iPSC BMEC BBBs after 4 and 24hrs, n=3 each. 
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comparable in the low TEER case (7.36 ± 3.29 vs 8.69 ± 2.95), however, for the high TEER 
condition, the ANG-LCaP fluorescence (37.29 ± 41.98) was approximately three times 
greater than the no ANG LCaPs (11.56 ± 3.65). For accumulation from 4 to 24hrs, 
fluorescence increased 42% for non-decorated LCaPs and 54% for ANG-LCaPs in the low 
TEER models compared to 22% for both LCaPs in the high TEER models. ANG appears 
to have the greatest enhancement effect across BBBs of higher TEER values, particularly 
in the earlier 4hr time frame, which supports the literature that ANG facilitates penetration 
via transcytosis. In the low TEER condition, the barriers are more permeable and LCaPs 
may be passing through by paracellular and intercellular routes. With tighter barriers, 
LCaPs are restricted paracellularly but the ANG-LCaPs are facilitated by ANG to 
transcytose through the BMECs which results in higher accumulation. Although the 
relative increase in accumulation from 4 to 24hrs was equivalent for each LCaP in the high 
TEER models, this can be explained by the extended incubation time that enabled non-
decorated LCaPs to be transported via adsorptive mediated transcytosis which occurred 
with eventual contact to the cell surface. Absolute accumulation was still higher for the 
ANG-decorated LCaPs in all cases. One note is that the standard deviations for the ANG-
LCaPs in the high TEER conditions were quite large, and so a larger sample size may be 
recommended to support these results. Nonetheless, the transcytosis enhancement does 
match rates reported in literature, which suggests about a 1.5-4X improvement in 
penetration or accumulation for NPs tagged with ANG compared to un-targeted NPs (in 




ANG-LCaP Basolateral Accumulation Makes up a Small Percentage of the Overall Input 
While ANG-LCaPs may improve penetration through tight BBBs, the overall 
proportion of nanoparticles that crossed was extremely low. As shown in Figure 28, when 
compared to the LCaPs that remained at the top of the TW after 24hrs, less than 7% was 
observed in the bottom chamber. No difference in fluorescence at the top TW compartment 
 
 
Figure 28. Comparison of the LCaP fluorescence in the top (apical) and  bottom (basolateral) 
chambers of the BMEC model after 24hr hours. LCaPs with or without ANG in high and low 
TEER conditions, n=3 each. 
 
was observed between the high and low TEER conditions for each LCaP treatment. 
However, total fluorescence values for non-targeted LCaPs remaining in the top chamber 
were about 13% lower than the values for the ANG-LCaPs. This may seem 
counterintuitive, as the accumulation in the bottom chamber was less than that of ANG-
LCaPs, however the two measurements do not account for the other possible interactions 
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in the model. LCaPs start in solution on the apical side, but can 1) bind/adsorb to the cell 
surface, 2) get internalized by BMECs, 3) pass through the BMEC layer into the porous 
membrane, 4) stay in solution within the basolateral compartment, or 5) bind to or become 
internalized by cancer cells in the bottom chamber. Non-targeted NPs are more likely to be 
internalized via endocytosis or adsorption mediated transcytosis (AMT), and may have a 
longer dwell time inside the BMEC cells compared to the ANG-LCaPs transported via the 
RMT pathway. Once inside the cell, endocytosed LCaPs may be degraded or exported via 
efflux pumps, both of which could account for the decreased fluorescence in the top (and 
bottom) chamber(s).  
While the small percentage of LCaP that crossed the model BBB is unfortunate 
with respect to drug delivery, it is not unexpected. Previous (unpublished) work in the 
laboratory found that typically only 1-2% of ANG-targeted NPs were transcytosed. 
Nonetheless, put into a broader perspective, even 1% penetration through the BBB is an 
improvement over the 0% in vivo. However, based on the dose requirements from Chapters 
3 and 4, the low accumulation suggested that GFP reduction in the cancer cells residing 
beyond the BBB layer would be limited. 
 
ANG-Assisted Transcytosis is not Sufficient for GFP Knockdown 
The normalized fluorescent values for the MDA MB 231 GFP cells in the BBB 
model are reported in Figure 29. For comparison to the GFP cells incubated with TWs, 
GFP cells were directly administered 15nM or 80nM of GFP siRNA via LCaPs with or 




Figure 29. MDA MB 231 GFP cell fluorescence after 4hr incubation with GFP  siRNA LCaPs 
decorated with or without ANG. LCaPs administered directly (15nM or 80nM siRNA) or through 
a BMEC BBB. N=3. 
 
which was consistent with findings in Chapter 3. Although MDA GFP cells were observed 
to express low levels of LRP1, there was no significant difference in GFP expression 
between ANG-targeted and non-targeted LCaPs, which suggests that ANG did not alter 
cellular uptake. Therefore, it was assumed that protein reduction in GFP cells with the BBB 
was due solely to the accumulation of LCaPs that crossed the BBB. 
For cells incubated with LCaPs that had to cross the BBB, slightly greater 
knockdown was observed with ANG-LCaPs (99.29 ± 2.21% and 96.65 ± 1.82%, low and 
high TEER BBB) compared to no ANG LCaPs (100.49 ± 1.92% and 99.64 ± 0.40%, low 
and high TEER BBB) which showed GFP levels equivalent to the untreated controls. The 
ANG-LCaPs in the high TEER condition demonstrated about 3% GFP reduction compared 
to the low TEER condition, which correlated with the increased accumulation observed in 
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the bottom chamber. However, the knockdown in the BMEC model was not statically 
different from the untreated controls and additional studies were performed to try to 
improve transcytosis efficacy.  
 
Exploring the Effect of ANG Density on BBB Penetration and LCaP Accumulation 
In order to improve LCaP penetration, accumulation was analyzed as a function of 
ANG density. Initial studies were conducted using empty liposomes with ANG conjugated 
to the outer leaflet at varying surface densities. The studies were conducted with a 
microfluidic BBB model composed of murine bEND.3 cells. As shown in Figure 30, 
liposomes decorated with 1.5% ANG had a greater enhancement on BBB penetration than 
0.5% or 1% ANG. Using these results as a guide, varying ANG surface densities were 
tested for RMT of LCaP across the model human BBB established in TW.  
 
 
Figure 30. Permeability of liposomes decorated with varying ANG densities across  a bEND.3 
microfluidic BBB model.  
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Testing ANG Density 
LCaPs decorated with 0, 1.5, and 5% ANG were incubated at two different doses 
(50µl and 200µl) in BBB TW models (average TEER >700Ω∙cm2 in all cases), with 
assessments at several time points over 24 hours. Additionally, blank TWs were incubated 
with a medium dose (100µl) of 0% and 5% ANG-LCaPs. Figure 31 shows the resulting 
accumulation data for each ANG density, as well as a combined graph for inter-treatment 
comparison. For all tests conducted with the BMEC cells, the general accumulation pattern 
was similar with LCaP penetration occurring in the early (<2hr) time points (Figure 31). 
Curiously, LCaP did not continue to accumulate in the lower chamber beyond 4 hours. In 
the absence of the BBB, LCaP diffused continuously across the TW semiporous 
membrane, and the relationship between particle accumulation and time was 
approximately linear after an initial lag phase (Figure 31a, c). Total accumulation after 
24hrs was higher in the controls (no BBB) as might be expected without a barrier to hinder 





Figure 31. NBD-labeled LCaP accumulation across BMEC BBBs over 24hrs with a) 0% ANG, 
b) 1.5% ANG, or c) 5% ANG decoration administered at low (50µl) or high (200µl) doses. 
Medium (100µl) doses added to blank (no cell) TWs. n = 3, except n = 1 for blank TWs. 
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 Looking specifically at the non-targeted LCaPs (Figure 27a), the accumulation for 
both the low and high LCaP doses were essentially equivalent, with slightly greater end 
point accumulation at the high dose. The high TEER value indicated that LCaP would have 
to be trafficked through cells (transcellular) and not passively between the cells 
(paracellular) to gain access to the lower chamber. It was hypothesized that transcellular 
trafficking would occur only for LCaP decorated with ANG on the surface; however, there 
was appreciable penetration of the model BBB by LCaP without ANG. Most likely the 
undecorated LCaP were internalized via contact with the surface and a pathway such as 
adsorption mediated transcytosis (AMT). Thus, it is possible that a fraction of ANG-LCaP 
penetrated the BBB via a mechanism other than RMT. This was an unexpected finding and 
warrants additional study.  
ANG LCaP accumulated in the lower chamber more quickly than undecorated 
LCaP, plateauing after a few hours.  This result suggested that ANG had a significant role 
in LCaP transcytosis initially. Interestingly, NBD fluorescence in the lower chamber 
remained constant after approximately five hours for all formulations of the LCaP, which 
suggested that LCaP penetration of the BBB ceased. Transcytosis is an energy-dependent 
process, therefore cellular fatigue could have been responsible for the plateau in 
accumulation in the bottom chamber. Alternatively, the plateau could result from 
nanoparticles remaining within cells after endocytosis or adsorbing to the TW semiporous 
membrane after passing through the cells. 
As seen by the blank TW condition, there was still capacity for LCaPs to 
accumulate. One explanation for the initial lag phase of the LCaPs through blank TWs 
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could be LCaP adsorption to the membrane. This could also account for the plateau in the 
BMEC model if LCaPs began to absorb to the membrane once through the cells instead of 
diffusing into the lower chamber. 
 Comparing absolute fluorescence across ANG densities in the BMEC model 
suggests that 1.5% ANG was the most effective surface density for facilitating LCaP 
penetration of the model human BBB. This was contrary to what was hypothesized or 
indicated by the data from the previous ANG experiment (comparing 0% and 5% ANG 
LCaPs)—that increasing the ANG density would increase penetration. Several hypotheses 
were proposed for various aspects of the results: 
 
1. A high density of ligands saturates receptors or restricts internalization. At 
high ANG densities and LCaP doses, cellular receptors would saturate, resulting in 
no additional benefit from transcytosis. This could explain the low accumulation of 
the 5% ANG LCaPs. Increasing the density of ANG on the LCaPs could have also 
resulted in NP binding to multiple receptors on one or more cells which would have 
sterically hindered internalization. This phenomenon would have been exacerbated 
since the BMECs demonstrated strong expression of the receptors.  
To date, no prior known study has analyzed NP penetration of the BBB as a function 
of ANG NP density (and dose) in human BMECs. However, studies looking at 
RMT ligand density for glioma targeting in other models do report of ligand 
saturation [92, 93, 149, 150]. One study using a hCMEC/D3 TW model found that 
increasing overall dose of scFab-ANG initially increased the accumulation 291% 
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when raised from 50µg to 100µg, but only had a 16% increase when further raised 
to 200µg [93]. In another investigation, LDL conjugated to a T7 peptide 
demonstrated improved internalization in a bEND.3/C6 model, when decorated 
with more than 0.5mol% T7 [150]. However, above 4% there was no additional 
benefit observed. This aligns with what was observed for the LCaPs. The current 
data suggests that 1.5% ANG was most beneficial for LCaP penetration. It was also 
observed in a separate experiment that 1.5% ANG had better accumulation than 
2.5% ANG-LCaPs (not shown). It has been estimated that BMECs in humans 
express at least 10% more LRP1 than BMECs in animals [102]. This number is 
likely even higher when compared to in vitro culture with immortalized cell lines. 
Previous targeting studies with ANG in animal or immortalized cell lines would 
not have reflected this difference, and these rough estimates may explain why 1.5% 
ANG seems to be optimal for the LCaPs.  
2. Cellular fatigue. Early (<2hr) time points displayed faster NP accumulation with 
ANG-decoration, however this plateaued with time. Because RMT is energy-
dependent, the cells may fatigue after several rounds of transcytosis. Literature 
documentation of ANG-targeted NPs report relatively quick (~15min-1hr) RMT, 
with peak accumulation around 2hrs [148, 151]. Therefore, it is likely that the cells 
experienced at least at least 2-8 rounds of transport. If 5% ANG actually resulted 
in faster transport initially, but fatigued the cells more quickly, initial accumulation 




3. Limited receptor recycling. Though RMT has been reported to be relatively quick, 
receptor recycling may not be as fast or may be limited by membrane re-orientation 
(i.e. remains on the basolateral side after release). This would result in an initial 
rapid accumulation, followed by a reduction and possible cessation in transcytosis.  
4. No cellular differentiation between the apical and basolateral sides. In the 
BBB, the ECs are polarized and receptor expression is specific and different for the 
apical and basolateral sides of the ECs [71, 112, 144]. Because the BMECs for the 
models used here were grown in monoculture, they did not receive environmental 
cues beyond the membrane support and col/FN coating. Other signals found in vivo 
that typically help distinguish orientation (i.e. neuronal cells, astrocyte or pericyte 
signaling factors, shear stress from flowing blood, etc.) were absent, and it is 
possible that LCaPs were expelled on the apical side. 
5. LCaP adhesion or membrane blockage. The lag phases in the blank TWs as well 
as the plateau in LCaP accumulation in the lower chamber suggest potential 
adhesion of the LCaPs onto the membrane (or col/FN coating), blockage of the 
pores, or aggregation of the LCaPs. In order to analyze LCaP trafficking, the BMEC 
layer and membrane were imaged with confocal microscopy. Figure 32 shows 





Figure 32. Confocal analysis of the BMEC membrane layer. Side view of the membrane 
(top) and underside of the membrane (bottom). DAPI in blue (nuclei), rhodamine in red 
(ANG-LCaP), and CY5 in green (LCaP siRNA). 
 
6.  While CY5 and rhodamine fluorescence appeared in punctate spots within the cell, 
a majority appeared to be outside of the BMECs with a significant proportion below 
(rather than above) the BMECs. This is promising because it demonstrates that the 
ANG-LCaPs were able to penetrate the BBB, likely via RMT. The preliminary data 
suggest that LCaPs pass through the BMEC layer but seem to be localized inside 
apical 
basolateral 
underside of membrane 
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the pores. From the bottom view it appears that the LCaPs were either adhering to 
the edges or inside of the pores within the membrane. Additionally, there is co-
localization of the red and green (yellow), indicating that the LCaPs remained 
intact. However, the DAPI stain also appeared to saturate the membrane and might 
be causing cross-fluorescence. For future studies, the sample preparation protocol 
would need to be optimized to stain cells on the membrane and improve membrane 
removal from the TW support for imaging. 
7. Established TEER thresholds are not accurate representations. At such high 
TEER values (ie: >>250Ω∙cm2), the assumption is that the LCaPs experience 
functionally equivalent restriction by the barrier. However, it was assumed that the 
electrical resistance and thus the permeability was uniform across the BBB. It was 
also assumed that TEER and permeability did not change over time. However, 
empirical data across several experiments show that the TEER values drop with 
time in the monoculture BBBs, which may affect the LCaP permeability. Specific 
TEER results for this experiment will be discussed further below. 
 
Analyzing TEER 
Based on previous literature and experimental data, the work in this dissertation 
used the assumption that barriers >250Ω∙cm2 were much less permeable to LCaPs. 
However, this threshold may be an outdated or overly generous value based on the 
achievable barrier TEERs at the time of those studies. There is likely more nuanced 
variation in solute and NP penetration/permeability even at high TEER values. Newer 
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models, which report iPSC BMECs with TEER up to 6000 Ω∙cm2 that remains relatively 
constant out to 21 days [152, 153], may usher in new investigations and enable more 
detailed evaluation of RMT-assisted NP permeability. 
 For the ANG density analysis, the reported TEER was based on the lowest TEER 
value during the experiment. However, TEER values were initially in the 1800-2000Ω∙cm2 
range, but fell during the course of the experiment as displayed in Figure 33.  
 
 
Figure 33. TEER time course of BMEC BBBs incubated with LCaPs decorated  with 0-5% ANG 




 The general pattern of TEER values (out to 4hrs) ordered from low to high followed 
the accumulation levels of the 0%, 1.5% and 5% ANG LCaPs in each dosing scheme. At 
2 hrs, the averaged TEER values for the 3 low dose treatment groups were close in value 
at 1857.71 ± 71.90, 1971.57 ± 43.21, and 2148.91 ± 307.43Ω∙cm2 for the 0%, 1.5%, and 
5% ANG LCaPs respectively. The averaged TEER values for the 3 high dose treatment 
groups were 714.56 ± 110.15, 965.81 ± 25.58, and 1554.56 ± 144.16Ω∙cm2 for the 0%, 
1.5%, and 5% ANG LCaPs respectively. It is unclear if the variation in TEER levels was 
due to the specific LCaPs or to the initial assignment of TWs with higher TEER to the 
higher ANG conditions. If the barriers at these TEER values were assumed to be 
functionally equal, then it could be concluded that the 1.5% ANG density improved LCaP 
accumulation compared to the 5% ANG density (at both doses and also when compared to 
the 0% ANG density). If not, then the only deviation between TEER order and 
accumulation is in the 1.5% ANG-LCaP high dose, which despite having higher TEER 
than the high dose 0% ANG-LCaPs, did experience more accumulation across the BBB.  
It is important to note that previous studies using ANG-decorated cargo/NPs in in 
vitro BBB models primarily utilized primary rat BMECs or immortalized EC lines (i.e. 
bEND.3, hCMEC/D3) [91, 93, 95, 142, 151]. Other studies used rat tumor animal models 
or only looked at internalization (and not penetration) within immortalized cell lines [92, 
93, 95, 99, 100, 149, 154, 155]. Due to lower TEER/higher permeability as well as lower 
expression of LRP1 (compared to human BMECs) [102, 105, 106, 108, 156, 157], these 
studies may have overinflated the benefit or penetration efficacy of ANG (as demonstrated 
earlier in this dissertation with the experiments utilizing TEER values below 400Ω∙cm2). 
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They almost certainly failed to capture the nuanced and restricted penetration mechanics 
suggested by the human iPSC BMEC model. Despite the emergence of several iPSC 
BMEC BBB model variations and characterization of those models for receptor expression, 
few solute or drug permeability studies have been conducted using the iPSC BMECs [152, 
157-163]. In fact, only a handful of in depth studies have been reported for differentiated 
BMECs [164-166], with few assessing ligand penetration or specifically ANG [167-170]. 
Furthermore, many of the in vitro models incorporating the iPSC BMECs have been 
microfluidic-based designs, such as the “Organ-on-a-Chip” [166]. While able to add 
physiological relevance (i.e. flow, shear stress, cell-to-cell contact, etc.), these designs 
require access to microfabrication centers or 3D printing machines and may not be as 
available or user-friendly as a Transwell model. Therefore, there is utility in pursuing 
further characterization, optimization, and assessment of ANG-NP penetration in the 
BMEC Transwell model.  
 
5.4 Limitations, Challenges, and Future Suggestions 
A major limitation of this chapter was the variability of the BMEC TEER. When 
BBBs had TEER >1000Ω∙cm2, the system was fairly stable on its own. However, BMECs 
in the 100-600Ω∙cm2 range sporadically experienced unexpected drops in TEER on Day 
10, despite the recommendation of peak TEER 48hrs after TW plating. This made it more 
difficult to choose the optimal time frame to start experiments, and may have resulted in 
experiments conducted with less than ideal TEER levels, despite initially high and 
anticipated TEER. In addition, other complications were experienced with the 
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differentiation at various periods, yet there was difficulty pinpointing the exact cause due 
to the extensive number of inputs and variables during the 2-3 week long differentiation 
process. The variability may have been due to user handling, but researchers would benefit 
from more consistent BMEC BBBs. The original authors of the differentiation protocol 
have also acknowledged variation that can arise from user differences as well as differences 
in reagent lots, notably platelet-poor plasma-derived serum (PDS). To improve the process 
and make it more affordable for researchers, they recently published a new shortened 
protocol utilizing serum-free media [152]. The resulting BMEC culture achieved TEER up 
to 6000-8000Ω∙cm2 that could be sustained for up to 3 weeks.  
LCaP treatment was also found to affect TEER levels at high doses, and future 
penetration experiments would benefit from more stable TEER during experiments in order 
to reduce the variables that could affect transcytosis assessment. Potential ways to stabilize 
the TEER levels for experiments include hydrating the LCaPs in media (vs buffer), 
switching to the new differentiation method, or co-culturing the BMEC models with 
astrocytes or pericytes. 
 
Interestingly, the iPSC differentiation protocol in 2012 stated that the differentiated 
BMECs did not express LRP1 in monoculture, but did with astrocyte co-culture. The 
validation performed in this chapter, however, confirmed LRP1 expression of the 
monoculture. The inclusion of retinoic acid (added to the 2015 protocol) may have been a 
factor, but the extent to which LRP1 is consistently expressed on the differentiated BMECS 
has not been quantified, and would be more reliable for comparison across studies with 
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different BMEC sets. However, because LRP1 was shown to express relatively strongly 
according to Western Blot, it was assumed for these studies that the same magnitude of 
expression level occurred in all the differentiations and that within batch comparisons were 
equivalent. Quantification of the exact number of LRP1 receptors (as well as the exact 
number of ligands on the LCaP surface) would be beneficial for future ANG density 
studies. 
An additional caveat is that LRP1 is a ubiquitous receptor, binding to many 
different ligands and expressed (at least on low levels) on various cell types. While reported 
to be overexpressed in brain ECs and gliomas, it is also upregulated in breast tissue, adipose 
tissue, and in the liver. LCaP off-targets may pose a problem for siRNA dosing, but because 
the EGFRvIII is highly specific to GBM, the effect on unintended cells should be minimal. 
However, the reduced availability of those NPs should be taken into account and reflected 
in the total administered dose. 
 
Additional suggestions for future experiments to improve upon the model BBB 
platform as well as study RMT fundamentally in order to optimize LCaP penetration 
include the following: 
1. Adding flow and/or transferring the BMECs and GFP cells to a microfluidic 
device BBB model. Adding a flow component to the BBB model would 
incorporate circulation found in vivo, which while counterintuitive, has actually 
been shown to improve transcytosis [142]. It should also enable more accurate 
RMT assessment since NPs will be in motion and ligand binding would play a 
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larger role for penetration/accumulation compared to simple NP contact (e.g. via 
AMT). Flow could also improve BMEC polarization of the lumial/abluminal faces 
of the BBB model, which would distinguish the cell surface for receptor 
localization and RMT direction. For Tranwells, a simple way to simulate fluid flow 
may be to gently shake the plates on an orbital shaker [149]. One example of a 
microfluidic device used for a flow model is depicted in Figure 34.  
 
 
Figure 34. Schematic of a BBB microfluidic device composed of two PDMS channels separated 
by a semipermeable membrane and adhered to a glass coverslip. 
 
2. Incorporating other cell types (astrocytes, pericytes) for a co- or tri-culture 
system. It has been demonstrated in literature that adding astrocytes in co-culture 
improves the TEER and “longevity” of the BBB. This could help stabilize the 
system and TEER, and provide an even tighter barrier for more consistent and 
physiologically accurate assessment of transcytosis/penetration.  
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3. Using an alternative or additional RMT ligand for penetration. This chapter 
specifically studied ANG trancytosis, but other RMT ligands can be evaluated or 
incorporated with ANG. Reducing the densities of each on an NP could improve 
overall internalization and BBB penetration.   
4. Characterizing the permeability of NPs (LCaPs, liposomes, etc.) of various 
known sizes (ie: 50, 100, 200, 400nm). A detailed analysis of nanoparticle size on 
BMEC BBB penetration as a function of TEER and permeability would be 
extremely useful for other NP therapeutics. This “library” of knowledge could 
inform future drug/nanocarrier design and experiments. 
 
5.5  Conclusions 
In this chapter, a micelle-based protocol was developed to conjugate Angiopep-2 
to DSPE-PEG-maleimide via a thiol-maleimide reaction. iPSCs were successfully 
differentiated into BMECs monolayers with TEER up to 2000Ω∙cm2, and the resulting cells 
were confirmed to strongly express LRP1. BMEC monocultures grown with or without 
retinoic acid displayed correspondingly different TEER and FITC-dextran permeability 
coefficients, which were within an order of magnitude for those reported in literature for 
the same and other cell types (e.g. bEND.3). ANG appeared to improve LCaP penetration 
in BBBs models with TEER values >200Ω∙cm2, but still resulted in insufficient siRNA 
delivery for significant knockdown of GFP in cancer cells across the BBB. Additional 
investigation of ANG LCaP density on penetration efficacy revealed complex interactions 
of the BMEC TW system, and suggestions for future experiments were recommended.  
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Overall, the iPSC BBB model demonstrates strong exclusion of solutes and NPs, 
and is likely a better predictor for in vivo results with its higher TEER and lower 
permeability as well as its human cell origins. The few in depth studies analyzing ANG-
decorated cargo across an in vitro BBB utilized primary rat ECs or immortalized cell lines 
(bEND.3, hCMEC/D3) and may have overestimated the ANG transcytosis efficacy. This 
is one of the first studies to analyze ANG-assisted NP transcytosis with human-derived 
BMECs. Although modifications may be necessary for reliable and reproducible data, the 
reduced permeability compared to current BBB models can enable more stringent NP or 
drug testing before moving into animal models and clinical trials, and should help reduce 





CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Conclusions 
This work demonstrated the tunability of the LCaP characteristics based on the 
Ca/P ratio, which can improve the desired siRNA loading and pharmacokinetics of the 
NPs. Experiments in vitro demonstrate the ability to successfully knockdown both GFP 
and the GBM-specific oncoprotein EGFRvIII. The dose-dependent knockdown of 
EGFRvIII and subsequent reduction in the viability of human GBM cells engineered to 
express the receptor confirm EGFRvIII as a viable therapeutic target. Potentially, siRNA-
induced silencing of EGFRvIII expression may be effective against GBM in patients as a 
monotherapy or in combination with a cytotoxic agent. The ligand ANG, which facilitates 
receptor-mediated transcytosis across the BBB, was conjugated to the lipid coating of the 
LCaP to enable transport of the nanocarrier through the barrier. The capacity of ANG-
decorated LCaPs to penetrate the BBB was tested in an in vitro model of the human BBB 
established in Transwells.  The results show that ANG did enhance LCaP penetration of 
the BBB, most likely via trafficking through the endothelial cell layer, and that a 1.5% 
ANG density was optimal for LCaP accumulation in the lower chamber. Despite an 
increase in penetration, the siRNA dose in the LCaP that accumulated in the lower chamber 
was insufficient to cause knockdown in cancer cells protected by the BBB.  However, this 
was one of the first studies to analyze the ANG-assisted penetration of a nanoparticle across 
a fully human-derived BBB model. Additional work can be performed to tease out the 
nuances of the model and study the penetration mechanics in depth. Overall the LCaPs are 
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shown to be an effective siRNA delivery platform, and the iPSC BMEC model is a more 
stringent and representative barrier for assessing penetration and delivery across the human 
BBB.  
 
6.2 Future Directions 
While specific experiments and future work were included in each aim, at a broader 
level the LCaP platform can be used for many other therapeutics. Although this dissertation 
analyzes the delivery of EGFRvIII siRNA, the particle is not limited by the genetic target 
or type of oligo it carries. In theory, any negatively charged, aqueous-soluble molecule 
could be delivered, but some potential cargo for the gene delivery space include miRNA, 
plasmid DNA, and CRISPR gRNA/Cas9 plasmids. Aqueous-soluble drugs could be co-
delivered within the CaP core or hydrophobic drugs could be added within the lipid bilayer. 
Additionally, other targeting peptides or antibodies (or even cargo) could be attached to 
the lipid shell for improved penetration or specificity to other diseases.  
The BBB model depicted here is a great start for a more stringent therapeutic 
screening platform. Newer iterations of the BMEC differentiation have been reported 
recently and could be adopted for more exhaustive studies exploring the relationship 
between BBB penetration and nanoparticle size, shape, and ligand surface density. Few 
studies have analyzed the permeability of small solutes and drugs in an in vitro human-
derived model, let alone targeted nanoparticles. While not trivial and fairly time 
consuming, the utility in developing a library relating nanoparticle and solute permeability 
for various sized molecules to TEER values is monumental. In particular, specific 
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evaluation of RMT ligands for penetration could greatly impact the drug delivery field. 
Overall, the option of an in vitro model may be more economical and more representative 
of the human BBB than an animal model, enabling rigorous assessment of therapies before 
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